Lineage Cell Therapeutics (LCTX) 10-K 15 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 13, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	BIOTIME INC
Entity Central Index Key	876,343
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 223,153,000
Entity Common Stock, Shares Outstanding		126,869,152
Trading Symbol	BTX
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017		Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 36,838		$ 22,088
Available-for-sale securities	1,337		627
Trade accounts and grants receivable, net	780		446
Landlord receivable			200
Receivable from affiliates, net	2,266		511
Prepaid expenses and other current assets	1,402		1,777
Total current assets	42,623		25,649
Property, plant and equipment, net	5,533	[1]	5,529	[2]
Deposits and other long-term assets	1,018		1,149
Intangible assets, net	6,900	[1]	10,206	[2]
TOTAL ASSETS	173,241		142,572
CURRENT LIABILITIES
Accounts payable and accrued liabilities	5,718	[1]	7,144	[2]
Capital lease and lease liability, current portion	212		202
Promissory notes, current portion	152		99
Related party convertible debt			833
Deferred license and subscription revenue, current portion	488		572
Deferred revenues	309
Total current liabilities	6,879		8,850
LONG-TERM LIABILITIES
Deferred revenues, net of current portion			308
Deferred rent liabilities, net of current portion	105		50
Lease liability, net of current portion	1,019		1,386
Capital lease liability, net of current portion	132		310
Related party convertible debt, net of discount			1,032
Promissory notes, net of current portion	18		120
Liability classified warrants and other long-term liabilities	825		8
TOTAL LIABILITIES	8,978		12,064
Commitments and contingencies (Note 12)
SHAREHOLDERS’ EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of December 31, 2017 and 2016, respectively
Common stock, no par value, authorized 150,000 shares; 126,866 shares issued and outstanding as of December 31, 2017 and 103,396 shares issued and 102,776 outstanding as of December 31, 2016	378,487		317,878
Accumulated other comprehensive income (loss)	451		(738)
Accumulated deficit	(216,297)		(196,321)
Treasury stock at cost: no shares as of December 31, 2017; 620 shares as of December 31, 2016			(2,891)
BioTime, Inc. shareholders’ equity	162,641		117,928
Noncontrolling interest	1,622		12,580
Total shareholders’ equity	164,263		130,508
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	173,241		142,572
OncoCyte Corporation [Member]
CURRENT ASSETS
Equity method investment at fair value	68,235
Asterias Biotherapeutics [Member]
CURRENT ASSETS
Equity method investment at fair value	$ 48,932		$ 100,039
[1]	Reflects the effect of the OncoCyte Deconsolidation.
[2]	Reflects the effect of the Asterias Deconsolidation

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock no par value
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, no par value
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	126,866,000	103,396,000
Common stock, shares outstanding	126,866,000	102,776,000
Treasury stock, shares		620,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
REVENUES:
Grant revenue	$ 1,666,000	$ 3,671,000	$ 4,502,000
Royalties from product sales and license fees	389,000	544,000	719,000
Subscription and advertisement revenues	1,395,000	972,000	1,357,000
Sale of research products and services	8,000	736,000	458,000
Total revenues	3,458,000	5,923,000	7,036,000
Cost of sales	(168,000)	(358,000)	(1,107,000)
Gross profit	3,290,000	5,565,000	5,929,000
OPERATING EXPENSES:
Research and development	(24,024,000)	(36,106,000)	(42,604,000)
General and administrative	(19,922,000)	(28,426,000)	(29,134,000)
Total operating expenses	(43,946,000)	(64,532,000)	(71,738,000)
Gain on sale of assets	1,754,000
Loss from operations	(38,902,000)	(58,967,000)	(65,809,000)
OTHER INCOME/(EXPENSES):
Interest expense, net	(692,000)	(747,000)	(340,000)
BioTime’s share of losses and impairment in equity method investment in Ascendance		(4,671,000)	(35,000)
Loss on extinguishment of related party convertible debt	(2,799,000)
Gain on investment			3,694,000
Other income/(expense), net	1,449,000	(403,000)	(160,000)
Total other income, net	15,613,000	77,588,000	3,159,000
INCOME (LOSS) BEFORE INCOME TAX BENEFIT	(23,289,000)	18,621,000	(62,650,000)
Deferred income tax benefit			4,516,000
NET INCOME (LOSS)	(23,289,000)	18,621,000	(58,134,000)
Net loss attributable to noncontrolling interest	3,313,000	14,951,000	11,143,000
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	(19,976,000)	33,572,000	(46,991,000)
Dividends on preferred shares			(415,000)
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (19,976,000)	$ 33,572,000	$ (47,406,000)
NET INCOME (LOSS) PER COMMON SHARE:
BASIC	$ (0.17)	$ 0.35	$ (0.59)
DILUTED	$ (0.17)	$ 0.34	$ (0.59)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC	114,476,000	97,316,000	79,711,000
DILUTED	114,476,000	99,553,000	79,711,000
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
Gain on deconsolidation	$ 71,697,000
Gain (loss) on equity method investment at fair value	(2,935,000)
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
Gain on deconsolidation		49,048,000
Gain (loss) on equity method investment at fair value	$ (51,107,000)	$ 34,361,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
NET INCOME (LOSS)	$ (23,289)	$ 18,621	$ (58,134)
Other comprehensive income/(loss), net of tax:
Foreign currency translation adjustment, net of tax	668	(106)	(424)
Available-for-sale investments:
Unrealized gain/(loss) on available-for-sale securities, net of taxes	521	(395)	1
COMPREHENSIVE INCOME (LOSS)	(22,100)	18,120	(58,557)
Less: comprehensive loss attributable to noncontrolling interest	3,313	14,951	11,143
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS BEFORE PREFERRED STOCK DIVIDEND	(18,787)	33,071	(47,414)
Preferred stock dividend			(415)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (18,787)	$ 33,071	$ (47,829)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders’ Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Common Shares [Member]Asterias Biotherapeutics [Member]	Common Shares [Member]OncoCyte [Member]	Common Shares [Member]AgeX [Member]	Treasury Shares [Member]OncoCyte [Member]	Treasury Shares [Member]	Contributed Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]Asterias Biotherapeutics [Member]	Noncontrolling Interest [Member]AgeX [Member]	Noncontrolling Interest [Member]OncoCyte Corporation [Member]	Noncontrolling Interest [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Total
Balance at Dec. 31, 2014	$ 3,500,000	$ 234,843,000					$ (19,890,000)	$ 7,000	$ (182,190,000)				$ 26,267,000	$ 186,000	$ 62,723,000
Balance, shares at Dec. 31, 2014	70,000	83,122,000					(4,894,000)
Sale of common shares, net of fees paid and amortized		$ 33,897,000													33,897,000
Sale of common shares, net of fees paid and amortized, shares		10,738,000
Exercise of options		$ 621,000													621,000
Exercise of options, shares		155,000
Warrants exercised		$ 19,000													19,000
Warrants exercised, shares		4,000
Stock options granted for compensation		$ 2,003,000													2,003,000
Stock options granted for compensation in subsidiaries													8,223,000		8,223,000
Restricted stock granted for compensation													822,000		822,000
Dividend in kind									(712,000)				712,000
Subsidiary shares retired to pay for employee's taxes													(98,000)		(98,000)
Subsidiary warrants exercised													11,700,000		11,700,000
Contingently issuable subsidiary warrants													65,000		65,000
Sale of treasury stock		$ (496,000)					$ 1,857,000								1,361,000
Sale of treasury stock, shares							421,000
Conversion of preferred stock to common stock	$ (3,500,000)	$ 3,500,000
Conversion of preferred stock to common stock, shares	(70,000)	875,000
Dividends on preferred stock		$ (408,000)						(7,000)							(415,000)
Exercise of subsidiary options													33,000		33,000
Subsidiary shares issued in lieu of cash for services received													486,000		486,000
Outside investment in subsidiary with cash													3,918,000		3,918,000
Sale of subsidiary shares at- the- market, net of fees paid and amortized													9,646,000		9,646,000
Foreign currency translation adjustment														(424,000)	(424,000)
Unrealized loss on available-for-sale securities														1,000	1,000
Common shares issued to purchase Cell Cure ordinary shares and Cell Cure Notes from noncontrolling interests in Cell Cure
NET INCOME (LOSS)									(46,991,000)				(11,143,000)		(58,134,000)
Balance at Dec. 31, 2015		$ 273,979,000					$ (18,033,000)		(229,893,000)				50,631,000	(237,000)	76,447,000
Balance, shares at Dec. 31, 2015		94,894,000					(4,473,000)
Sale of common shares, net of fees paid and amortized		$ 18,606,000													18,606,000
Sale of common shares, net of fees paid and amortized, shares		8,420,000
Stock options granted for compensation		$ 2,731,000													2,731,000
Stock options granted for compensation in subsidiaries													5,220,000		5,220,000
Dividends on preferred stock
Exercise of subsidiary options													2,151,000		2,151,000
Foreign currency translation adjustment														(106,000)	(106,000)
Unrealized loss on available-for-sale securities														(395,000)	(395,000)
Common shares issued for executive bonus in lieu of cash		$ 200,000													200,000
Common shares issued for executive bonus in lieu of cash, shares		68,000
Common shares issued for consulting services in lieu of cash		$ 40,000													40,000
Common shares issued for consulting services in lieu of cash, shares		14,000
Deconsolidation							$ 15,142,000						(21,752,000)		(6,610,000)
Deconsolidation, shares							3,853,000
Subsidiary financing transactions with noncontrolling interests			18,310,000	4,012,000						(18,310,000)		(4,012,000)
Distribution of Asterias warrants to its shareholders other than BioTime													3,125,000		3,125,000
Sale of common shares and warrants by OncoCyte, net of financing fees													9,777,000		9,777,000
Beneficial conversion feature on convertible debt issued to Cell Cure's noncontrolling interests													701,000		701,000
Common shares issued to purchase Cell Cure ordinary shares and Cell Cure Notes from noncontrolling interests in Cell Cure
NET INCOME (LOSS)									33,572,000				(14,951,000)		18,621,000
Balance at Dec. 31, 2016		$ 317,878,000					$ (2,891,000)		(196,321,000)				12,580,000	(738,000)	130,508,000
Balance, shares at Dec. 31, 2016		103,396,000					(620,000)
Sale of common shares, net of fees paid and amortized		$ 45,068,000													45,068,000
Sale of common shares, net of fees paid and amortized, shares		18,511,000
Exercise of options		$ 25,000													25,000
Exercise of options, shares		9,000
Stock options granted for compensation		$ 3,019,000													3,019,000
Stock options granted for compensation in subsidiaries													913,000		913,000
Dividends on preferred stock
Exercise of subsidiary options													4,000		4,000
Foreign currency translation adjustment														668,000	668,000
Unrealized loss on available-for-sale securities														521,000	521,000
Common shares issued for consulting services in lieu of cash		$ 3,000													3,000
Common shares issued for consulting services in lieu of cash, shares		1,000
Deconsolidation				(3,253,000)		$ 2,891,000						$ (8,512,000)			(8,874,000)
Deconsolidation, shares						620,000
Subsidiary financing transactions with noncontrolling interests					$ 8,207,000						$ (8,207,000)
Beneficial conversion feature on convertible debt issued to Cell Cure's noncontrolling interests													304,000		304,000
Sale of common shares at the market, net of fees		$ 835,000													835,000
Sale of common shares at the market, net of fees, shares		300,000
Purchase of shares from a related party and retired		$ (843,000)													(843,000)
Purchase of shares from a related party and retired, shares		(300,000)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employee's taxes		$ (46,000)													(46,000)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares		24,000
Sale of subsidiary shares in AgeX					$ 100,000						$ 9,868,000				9,968,000
Subsidiary financing and other transactions with noncontrolling interests -LifeMap Sciences, LifeMap Solutions, OrthoCyte, and ReCyte, net		$ 5,495,000											(5,495,000)
Common shares issued to purchase Cell Cure ordinary shares and Cell Cure Notes from noncontrolling interests in Cell Cure		$ 15,217,000													15,217,000
Common shares issued to purchase Cell Cure ordinary shares and Cell Cure Notes from noncontrolling interests in Cell Cure, shares		4,925,000
Purchase of noncontrolling interests in Cell Cure		$ (10,117,000)											3,480,000		(6,637,000)
Purchase of beneficial conversion option at intrinsic value in Cell Cure Notes		(3,101,000)													(3,101,000)
NET INCOME (LOSS)									(19,976,000)				(3,313,000)		(23,289,000)
Balance at Dec. 31, 2017		$ 378,487,000							$ (216,297,000)				$ 1,622,000	$ 451,000	$ 164,263,000
Balance, shares at Dec. 31, 2017		126,866,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to BioTime, Inc.	$ (19,976,000)	$ 33,572,000	$ (46,991,000)
Net loss allocable to non-controlling interest	(3,313,000)	(14,951,000)	(11,143,000)
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
BioTime’s share of losses and impairment of Ascendance		4,671,000	35,000
Gain on sale of assets	(1,754,000)
Depreciation expense, including amortization of leasehold improvements	947,000	1,180,000	1,078,000
Amortization of intangible assets	2,349,000	3,577,000	5,256,000
Stock-based compensation	3,932,000	7,951,000	11,050,000
Liability classified warrants	797,000
Subsidiary shareholder expense for subsidiary warrants		3,125,000
Subsidiary common stock issued in lieu of cash for services			486,000
Amortization of discount on related party convertible debt	640,000	448,000	245,000
Deferred income tax benefit			(4,516,000)
Foreign currency remeasurement and other (gain) loss	(1,761,000)	2,251,000	345,000
Loss on extinguishment of related party debt	2,799,000
Changes in operating assets and liabilities:
Accounts and grants receivable, net	(172,000)	187,000	(80,000)
Due from affiliates	1,157,000
Prepaid expenses and other current assets	145,000	(1,115,000)	(1,533,000)
Other long-term assets and liabilities	(22,000)	(56,000)	(120,000)
Accounts payable and accrued liabilities	1,299,000	12,000	1,673,000
Accrued interest on related party convertible debt			19,000
Deferred revenues and grant income	243,000	132,000	3,285,000
Deferred grant expense	(227,000)
Deferred rent liabilities	55,000	99,000	61,000
Net cash used in operating activities	(30,517,000)	(42,326,000)	(44,544,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,326,000)	(2,248,000)	(1,241,000)
Payments on construction in progress		(278,000)	(4,093,000)
Purchase of foreign available-for-sale securities	(189,000)		(748,000)
Proceeds from sale of assets	200,000
Payment for Ascendance equity method investment			(500,000)
Security deposit paid and other	(12,000)	13,000	(859,000)
Net cash used in investing activities	(10,225,000)	(10,889,000)	(7,441,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares	48,875,000	20,125,000	35,470,000
Fees paid on sale of common shares	(3,798,000)	(1,515,000)
Proceeds from sale of subsidiary common shares and warrants	9,968,000	10,721,000	13,639,000
Fees paid on sale of subsidiary common shares and warrants		(879,000)	(693,000)
Proceeds from sale of common shares at-the-market, net of fees	835,000
Purchase and retirement of common shares from a related party	(843,000)
Proceeds from issuance of related party convertible debt	425,000	1,757,000	255,000
Reimbursement from landlord on construction in progress	198,000	567,000	3,789,000
Proceeds from exercise of subsidiary stock options	4,000	2,151,000	33,000
Proceeds from exercise of stock options	25,000		621,000
Proceeds from exercise of warrants			20,000
Common shares received and retired for employee taxes paid	(45,000)
Repayment of lease liability and capital lease obligation	(204,000)	(145,000)	(59,000)
Repayment of promissory notes	(49,000)
Proceeds from exercise of subsidiary warrants			11,700,000
Net cash provided by financing activities	55,391,000	32,782,000	64,775,000
Effect of exchange rate changes on cash and cash equivalents	101,000	292,000	(48,000)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	14,750,000	(20,141,000)	12,742,000
CASH AND CASH EQUIVALENTS:
At beginning of year	22,088,000	42,229,000	29,487,000
At end of year	36,838,000	22,088,000	42,229,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during year for interest	156,000	94,000	119,000
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:
BioTime common stock issued to purchase Cell Cure ordinary shares and Convertible Notes from noncontrolling interests in Cell Cure	15,217,000
Extinguishment of related party convertible debt, including accrued interest, with BioTime common stock	2,680,000
Capital expenditure funded by capital lease liability	151,000	626,000	34,000
Construction in progress in accounts payable and accrued expenses			524,000
Landlord receivable			567,000
Lease liability		1,385,000	4,400,000
Conversion of preferred stock to common stock			3,500,000
Promissory notes in exchange of preferred share dividends			363,000
Common stock issued in lieu of cash for bonus and services		240,000
Equity method investment in Ascendance in exchange for assets			4,706,000
Asterias Biotherapeutics [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation		(49,048,000)
Unrealized (gain) loss on equity method investment in at fair value	51,107,000	(34,361,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents		(8,376,000)
OncoCyte Corporation [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation	(71,697,000)
Unrealized (gain) loss on equity method investment in at fair value	2,935,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents	$ (8,898,000)

Organization, Basis of Presenta

Organization, Basis of Presentation and Liquidity	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Basis of Presentation and Liquidity	1. Organization, Basis of Presentation and Liquidity General – HyStem ® HyStem ® BioTime’s lead cell replacement clinical product is OpRegen ® BioTime’s lead cell delivery clinical product is Renevia ® HyStem ® In 2017, BioTime formed AgeX Therapeutics, Inc. (“AgeX”) . AgeX will focus on the development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders. . AgeX may also pursue other early-stage programs. On August 17, 2017, AgeX completed an asset acquisition and stock sale pursuant to which it received certain assets from BioTime for use in its research and development programs and raised $10.0 million in cash from investors to finance its operations. This capitalization of AgeX As of December 31, 2017, BioTime owned approximately 85% of the issued and outstanding shares of AgeX common stock (see Notes 2 and 10). BioTime is also enabling early-stage programs in other new technologies through its own research programs as well as through other subsidiaries or affiliates. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (“Asterias”) and OncoCyte Corporation (“OncoCyte”), which BioTime founded and, until recently, were majority-owned and consolidated subsidiaries. Asterias (NYSE American: AST) is presently focused on advancing three clinical-stage programs that have the potential to address areas of high, unmet medical need in the fields of neurology (spinal cord injury) and oncology (acute myeloid leukemia and lung cancer). OncoCyte (NYSE American: OCX) is developing confirmatory diagnostic tests for lung cancer, breast cancer, and bladder cancer utilizing novel liquid biopsy technology. On February 17, 2017, BioTime’s ownership of OncoCyte declined below 50% after certain OncoCyte investors acquired OncoCyte common stock by exercising OncoCyte stock purchase warrants, and BioTime deconsolidated the financial statements of OncoCyte from its consolidated financial statements (the “OncoCyte Deconsolidation”) (see Note 3). Since February 17, 2017, BioTime has accounted for On May 13, 2016, BioTime BioTime’s percentage ownership in Asterias declined below 50% as a result of Asterias’ public offering of its common stock to raise capital for its operations and BioTime deconsolidated the financial statements of Asterias from its consolidated financial statements (the “Asterias Deconsolidation”) (see Note 3) , BioTime has accounted for the Asterias common stock it holds using the equity method of accounting at fair value (see Note 5). Use of estimates - Principles of consolidation Subsidiary Field of Business BioTime Ownership Country Cell Cure Neurosciences Ltd. (“Cell Cure”) Products to treat age-related macular degeneration 98.8% (1) Israel ES Cell International Pte. Ltd. (“ESI”) Stem cell products for research, including clinical grade cell lines produced under cGMP 100% Singapore OrthoCyte Corporation (“OrthoCyte”) Developing bone grafting products for orthopedic diseases and injuries 99.8% USA AgeX Therapeutics, Inc. (“AgeX”) PureStem ® 85.4% USA ReCyte Therapeutics, Inc. (“ReCyte Therapeutics”) (2) Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity 94.8% USA LifeMap Sciences, Inc. (“LifeMap Sciences”) (2), (3) Biomedical, gene, disease, and stem cell databases and tools 81.7% USA (1) Includes shares owned by BioTime and ESI (2) ReCyte Therapeutics and LifeMap Sciences are subsidiaries of AgeX (3) LifeMap Sciences, Ltd. (Israel) is a wholly-owned subsidiary of LifeMap Sciences All material intercompany accounts and transactions have been eliminated in consolidation. As of December 31, 2017, BioTime consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders’ equity on BioTime’s consolidated balance sheets. Liquidity – sufficient cash, cash equivalents, and liquidity to carry out BioTime’s current operations through at least twelve months from the issuance date of the consolidated financial statements included herein. BioTime also holds shares of Asterias and OncoCyte common stock with a combined value of $117.2 million at December 31, 2017. Although BioTime has no present plans to liquidate its holdings of Asterias or OncoCyte shares, if BioTime needs near term working capital or liquidity to supplement its cash and cash equivalents for its operations, BioTime may sell some, or all, of its Asterias or OncoCyte shares, as necessary. BioTime’s projected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meet future capital needs could force it to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on its evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, and projection of future costs, revenues, and rates of expenditure. For example, clinical trials being conducted for its OpRegen ® OpRegen ® As further discussed in Note 10, on August 17, 2017, AgeX completed an asset acquisition and stock sale pursuant to which it received certain assets from BioTime for use in its research and development programs and raised $10.0 million in cash from investors to finance its operations. However, BioTime cannot assure that adequate financing will be available to AgeX in the future to fund the AgeX programs.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Going concern assessment – Revenue recognition Accounting Standards Codification Research and Development Arrangements Cost of sales Cash and cash equivalents Restricted cash Trade accounts and grants receivable, net – Concentrations of credit risk Fair Value Measurements Fair Value Measurements and Disclosures ● Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value. In determining fair value, BioTime utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, BioTime has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds, shares BioTime holds in Asterias and OncoCyte and the available-for-sale securities, which are carried at fair value based on the applicable period-end quoted market prices as a Level 1 input. BioTime also has certain liability classified warrants issued by Cell Cure which are carried at fair value based on Level 3 inputs (see Note 10). The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items. Equity method accounting for Asterias and OncoCyte, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations in other income and expenses, net. As further discussed in Notes 4 and 5, BioTime has elected to account for its Asterias and OncoCyte shares at fair value using the equity method of accounting because beginning on May 13, 2016 and February 17, 2017, the respective dates on which BioTime deconsolidated Asterias and OncoCyte, BioTime has not had control of Asterias and OncoCyte, as defined by GAAP since the applicable deconsolidation dates, but BioTime continues to exercise significant influence over Asterias and OncoCyte. Under the fair value method, the value of the shares of common stock BioTime holds in Asterias and OncoCyte is marked to market at each balance sheet date using the closing prices of Asterias and OncoCyte common stock on the NYSE American multiplied by the number of shares of Asterias and OncoCyte held by BioTime, with changes in the fair value of the Asterias and OncoCyte shares included in other income and expenses, net, in the consolidated statements of operations. The Asterias and OncoCyte shares are considered level 1 assets as defined by ASC 820. Available-for-sale securities in foreign investments Investments – Debt and Equity Securities Property, plant and equipment, net Long-lived intangible assets Impairment of long-lived assets – Treasury stock – Accounting for warrants – Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock Investments in Common Stock of Privately Held Companies – Investments – Equity Method and Joint Ventures BioTime initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on BioTime’s share of earnings or losses from the investment included in other income or expenses, net, on the consolidated statements of operations. The equity method investment balance is shown in noncurrent assets on the consolidated balance sheets. BioTime reviews investments accounted for under the equity method for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be fully recoverable. If a determination is made that an “other-than-temporary” impairment exists, BioTime writes down its investment to fair value. Based on an evaluation and continuing losses and negative cash flows generated from the Ascendance investment, including uncertainty as to Ascendance’s ability to raise sufficient financing, BioTime determined that an other-than-temporary impairment existed on its equity method investment in Ascendance as of December 31, 2016, and BioTime wrote down the entire remaining $3.5 million carrying value of that investment included in other income and expenses, net. Transactions with Noncontrolling Interests of Subsidiaries – 810-10-45-23, Consolidation Other Presentation Matters, Research and development – General and administrative stock exchange-related costs, depreciation expense, marketing costs, and other miscellaneous expenses which are allocated to general and administrative expense Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses – For transactions denominated in other than the functional currency of BioTime or its subsidiaries, BioTime recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The majority of BioTime’s foreign currency transaction gains and losses are generated by Cell Cure’s intercompany debt due to BioTime (see Note 9), which are U.S. dollar-denominated, while Cell Cure’s functional currency is NIS. Accordingly, foreign currency remeasurement gains and losses related to this debt are included in other income and expenses, net. Income taxes – BioTime accounts for income taxes in accordance with ASC 740, Income Taxes On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (“AMT”), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (“NOLs”) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer’s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax “deemed repatriation” on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 13). On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows BioTime to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 13). Stock-based compensation – orfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09. Based on the nature and timing of grants, straight line expense attribution of stock-based compensation for the entire award and the relatively low forfeiture rates on BioTime’s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not material to the consolidated financial statements Certain of BioTime’s privately-held consolidated subsidiaries have their own share-based compensation plans. For share-based compensation awards granted by those privately-held consolidated subsidiaries under their respective equity plans, BioTime determines the expected stock price volatility using historical prices of comparable public company common stock for a period equal to the expected term of the options. The expected term of privately-held subsidiary options is based upon the “simplified method” provided under Staff Accounting Bulletin, Topic 14 Although the fair value of employee stock options is determined in accordance with FASB guidance, changes in the assumptions can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements. Basic and diluted net income (loss) per share attributable to common shareholders For the year ended December 31, 2016, the primary components of weighted average shares of potentially dilutive common shares used to compute diluted net income per common share were approximately 2,030,000 BioTime common shares held by Asterias and OncoCyte (see Note 10), and approximately 206,000 restricted stock units and outstanding stock options. For the years ended December 31, 2017 and 2015, b The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Year Ended December 31, 2017 2016 2015 Stock options 7,983 6,852 5,194 Warrants 9,395 9,395 10,109 Treasury stock 81 - 4,472 Adoption of ASU 2016-09 , Improvements to Employee Share-Based Payment Accounting Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In connection with the adoption of ASU 2016-09, BioTime changed its accounting policies, including how it accounts for excess tax benefits and deficiencies, if any, and forfeitures, as applicable. All excess tax benefits and tax deficiencies from stock based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. Prior to the adoption of ASU 2016-09, BioTime recognized excess tax benefits, if any, in additional paid-in capital only if the tax deduction reduced cash income taxes payable and, excess tax deficiencies were recognized as an offset to accumulated excess tax benefits, if any, on BioTime’s consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because BioTime had an insignificant number of stock option exercises during the year ended December 31, 2017, and because of BioTime’s full valuation allowance as of December 31, 2017 and 2016, the impact to BioTime’s consolidated statements of operations for any excess tax benefits or deficiencies was immaterial (see Note 13). Forfeitures are now accounted for as they occur instead of based on the number of awards that were expected to vest. Based on (i) the nature and timing of BioTime’s grants, straight line expense attribution of stock based compensation for the entire award, and (ii) the relatively low forfeiture rates on BioTime’s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not material to BioTime’s consolidated financial statements. Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgments and estimates may be required in the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The evaluation of the impact of adoption of ASU 2014-09 (Topic 606) on existing contracts with customers is still in process; however, BioTime does not expect the adoption of the new guidance will have a material impact to its consolidated financial statements. In performing this evaluation, BioTime has identified certain changes to business processes and internal controls relating to contracts and disclosures that are needed upon the adoption of the new guidance. BioTime will adopt this new standard on January 1, 2018, and plans on using the modified retrospective transition method, which requires the application of the new standard only to those contracts that were not completed as of the adoption date. Upon adoption of ASU 2014-09 and, if necessary, BioTime will recognize the cumulative effect of adopting this guidance as an adjustment to the opening consolidated accumulated deficit balance as of January 1, 2018. BioTime will continue to monitor industry activities and any additional guidance provided by regulators, standards setters, or the accounting profession and adjust its assessment and implementation plans accordingly. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that reporting period. Early adoption is permitted. BioTime is currently evaluating the impact the adoption of ASU 2016-02 will have on its consolidated financial statements. On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (ASU 2016-01). Changes to the GAAP model primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Based on the current accounting for ,

Deconsolidation of OncoCyte and

Deconsolidation of OncoCyte and Asterias	12 Months Ended
	Dec. 31, 2017
Deconsolidation of OncoCyte and Asterias [Abstract]
Deconsolidation of OncoCyte and Asterias	3. Deconsolidation of OncoCyte and Asterias On February 17, 2017, OncoCyte issued 625,000 shares of OncoCyte common stock to certain investors who exercised their OncoCyte warrants. The warrants had been issued as part of OncoCyte’s financing that was completed on August 29, 2016. As a result of the issuance of the 625,000 shares of OncoCyte common stock, beginning on February 17, 2017, BioTime owned less than 50% of the OncoCyte outstanding common stock and experienced a loss of control of the OncoCyte subsidiary. Under GAAP, loss of control of a subsidiary is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability to elect a majority of the subsidiary’s Board of Directors. BioTime determined that all of those loss of control factors were present with respect to OncoCyte on February 17, 2017. Accordingly, BioTime deconsolidated OncoCyte’s financial statements and results of operations from BioTime, effective February 17, 2017, in accordance with ASC, 810-10-40-4(c), Consolidation For periods on and after February 17, 2017, BioTime is accounting for its retained noncontrolling investment in OncoCyte under the equity method of accounting and has elected the fair value option under ASC 825-10, Financial Instruments In connection with the OncoCyte Deconsolidation and in accordance with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation of $71.7 million which is BioTime held 14.7 million shares of OncoCyte common stock, or approximately 46.7% of OncoCyte outstanding common stock, as of December 31, 2017. On May 13, 2016, Asterias completed the sale of 5,147,059 shares of its common stock and warrants to purchase 2,959,559 shares of its common stock, through an underwritten public offering (the “Asterias Offering”). As a result of the sale of Asterias common stock in the Asterias Offering and the issuance of 708,333 shares of Asterias common stock upon the exercise of certain stock options by a former Asterias executive, as of May 13, 2016, BioTime’s percentage ownership of the outstanding common stock of Asterias declined below 50%. ccordingly, BioTime has deconsolidated Asterias financial statements and results of operations from BioTime (the “Asterias Deconsolidation”), effective May 13, 2016, in accordance with ASC, 810-10-40-4(c), Consolidation Financial Instruments In connection with the Asterias Deconsolidation and in accordance with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation of $49.0 million during the year December 31, 2016 BioTime held 21.7 million shares of Asterias common stock, or approximately 40.2% of Asterias outstanding common stock, as of December 31, 2017.

Equity Method Accounting for Co

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value	12 Months Ended
	Dec. 31, 2017
Equity Method Accounting for Common Stock of OncoCyte, at fair value [Abstract]
Equity Method Accounting for Common Stock of OncoCyte, at Fair Value	4. Equity Method of Accounting for Common Stock of OncoCyte, at Fair Value BioTime elected to account for its 14.7 million shares of OncoCyte common stock shares had a fair value of $68.2 million as of December 31, 2017 and a fair value of $71.2 million as of February 17, 2017, based on the $4.65 per share and $4.85 per share closing prices of OncoCyte common stock on the NYSE American on those respective dates. For the year ended December 31, 2017, BioTime recorded an unrealized loss of $2.9 million due . The condensed results of operations and condensed balance sheet information of OncoCyte are summarized below (in thousands): For the Period January 1, 2017 through (1) Condensed Statement of Operations (1) Research and development expense $ 798 General and administrative expense 377 Sales and marketing expense 213 Loss from operations (1,388) Net loss $ (1,392) (1) OncoCyte’s condensed results of operations for the period from January 1, 2017 through February 16, 2017, the date immediately preceding the OncoCyte Deconsolidation, for the year ended December 31, 2017, and for the years ended December 31, 2016 and 2015, shown in the table below, are included in the consolidated results of operations of BioTime for those respective periods, after intercompany eliminations, as applicable. The following table summarizes OncoCyte results of operations for the full years ended December 31, 2017, 2016 and 2015 (in thousands). Condensed Statements of Operations Year Ended December 31, 2017 Year Ended December 31, 2016 Year Ended December 31, 2015 Research and development expense $ 7,174 $ 5,677 $ 4,527 General and administrative expense 9,232 4,265 3,867 Sales and marketing expense 2,443 1,198 324 Loss from operations (18,849) (11,140) (8,718) Net loss $ (19,375) $ (11,168) $ (8,735) December 31, 2017 December 31, 2016 Condensed Balance Sheet information (2) Current assets $ 8,528 $ 12,696 Noncurrent assets 1,688 1,751 $ 10,216 $ 14,447 Current liabilities $ 4,454 $ 4,275 Noncurrent liabilities 1,359 310 Stockholders’ equity 4,403 9,862 $ 10,216 $ 14,447 (2) The condensed balance sheet information of OncoCyte as of December 31, 2017 and 2016, is provided for informational and comparative purposes only. OncoCyte was not included in BioTime’s consolidated balance sheet at December 31, 2017.

Equity Method Accounting for 12

Equity Method Accounting for Common Stock of Asterias, at Fair Value	12 Months Ended
	Dec. 31, 2017
Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract]
Equity Method Accounting for Common Stock of Asterias, at Fair Value	5. Equity Method of Accounting for Common Stock of Asterias, at Fair Value BioTime elected to account for its 21.7 million shares of Asterias common stock The Asterias shares had a fair value of $100.0 million as of December 31, 2016 and a fair value of $65.7 million as of May 13, 2016, . For the year ended December 31, 2016, BioTime recorded an unrealized gain of $34.3 million on the Asterias shares due to the increase in Asterias stock price from May 13, 2016 to December 31, 2016. The condensed results of operations and condensed balance sheet information of Asterias are summarized below (in thousands): For the Period January 1, 2016 through (1) Condensed Statement of Operations (1) Total revenue $ 2,354 Gross profit 2,301 Loss from operations (13,944) Net loss $ (13,113) (1) Asterias condensed results of operations for the period from January 1, 2016 through May 12, 2016, the date immediately preceding the Asterias Deconsolidation, for the year ended December 31, 2016, and for the year ended December 31, 2015, shown in the table below, are included in the consolidated results of operations of BioTime for the years ended December 31, 2016 and 2015, respectively, after intercompany eliminations, as applicable. The following table summarizes Asterias results of operations for the full years ended December 31, 2017, 2016 and 2015 (in thousands). Condensed Statements of Operations Year Ended December 31, 2017 Year Ended December 31, 2016 Year Ended December 31, 2015 Total revenue $ 4,042 $ 6,954 $ 3,582 Gross profit 3,877 6,826 3,314 Loss from operations (33,251) (34,123) (21,908) Net loss $ (28,372) $ (35,489) $ (15,003) December 31, 2017 December 31, 2016 Condensed Balance Sheet information (1) Current assets $ 22,716 $ 36,990 Noncurrent assets 20,376 24,020 $ 43,092 $ 61,010 Current liabilities $ 3,521 $ 6,535 Noncurrent liabilities 6,028 12,447 Stockholders’ equity 33,543 42,028 $ 43,092 $ 61,010 (1) The condensed balance sheet information of Asterias as of December 31, 2017 and 2016, is provided for informational and comparative purposes only and was not included in BioTime’s consolidated balance sheet as of December 31, 2017 and 2016 due to the Asterias Deconsolidation on May 13, 2016.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	6. Property, Plant and Equipment, Net At December 31, 2017 and 2016, property, plant and equipment were comprised of the following (in thousands): December 31, 2017 (1) 2016 (2) Equipment, furniture and fixtures $ 4,255 $ 4,718 Leasehold improvements 4,434 3,791 Accumulated depreciation and amortization (3,156) (2,980) Property and equipment, net $ 5,533 $ 5,529 (1) Reflects the effect of the OncoCyte Deconsolidation. (2) Reflects the effect of the Asterias Deconsolidation Property, plant and equipment at December 31, 2017 and 2016 includes $151,000 and $626,000 financed by capital leases, respectively. Depreciation and amortization expense amounted to $0.9 million, $1.2 million and $1.1 million for the years ended December 31, 2017, 2016 and 2015, respectively. Leasehold improvements Leasehold improvements of approximately $1.6 million was transferred to property, plant and equipment as of June 1, 2016 when BioTime completed construction of leasehold improvements at its Alameda facility (see Note 12). Under the terms of the lease agreement, the landlord provided BioTime with an initial tenant improvement allowance of up to $1.4 million, which BioTime utilized entirely to construct a research and development laboratory, a diagnostic testing laboratory, and a small production facility that can be used to manufacture small cell banks and clinical materials for clinical studies. Additional leasehold improvements of approximately $200,000 paid by BioTime were not reimbursable by the landlord. The tenant improvements are amortized over the shorter of the useful life of the assets or the lease term.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	7. Intangible Assets, Net At December 31, 2017 and 2016, intangible assets, primarily consisting of acquired patents and accumulated amortization were as follows (in thousands): December 31, 2017 (1) 2016 (2) Intangible assets $ 23,294 $ 25,703 Accumulated amortization (16,394) (15,497) Intangible assets, net $ 6,900 $ 10,206 (1) Reflects the effect of the OncoCyte Deconsolidation. (2) Reflects the effect of the Asterias Deconsolidation BioTime amortizes its intangible assets over an estimated period of 10 years on a straight-line basis. BioTime recognized $2.3 million, $3.6 million and $5.3 million in amortization expense of intangible assets during the years ended December 31, 2017, 2016 and 2015, respectively. Amortization of intangible assets for periods subsequent to December 31, 2017 is as follows (in thousands): Year Ended December 31, Amortization Expense 2018 $ 2,338 2019 2,328 2020 1,553 2021 517 2022 164 Total $ 6,900

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	8. Accounts Payable and Accrued Liabilities At December 31, 2017 and 2016, accounts payable and accrued liabilities consist of the following (in thousands): December 31, 2017 (1) 2016 (2) Accounts payable $ 938 $ 1,593 Accrued liabilities 2,368 3,212 Accrued compensation 2,275 1,904 Other current liabilities 137 435 Total $ 5,718 $ 7,144 (1) Reflects the effect of the OncoCyte Deconsolidation (2) Reflects the effect of the Asterias Deconsolidation.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions Related Party Convertible Debt Cell Cure issued certain convertible promissory notes (the “Convertible Notes”) to Cell Cure shareholders other than BioTime. The functional currency of Cell Cure is the Israeli New Shekel however the Convertible Notes are payable in United States dollars. Consequently, at each balance sheet date, Cell Cure remeasures the Convertible Notes issued to BioTime and other Cell Cure shareholders using the current exchange rate at that date pursuant to ASC 830, Foreign Currency Matters. Derivatives and Hedging Debt with Conversion and Other Options . On July 10, 2017, BioTime purchased all of the outstanding Cell Cure Convertible Notes and Cell Cure ordinary shares held by H adasit Bio-Holdings Ltd. (“HBL”), a Cell Cure shareholder that owned 21.2% of the issued and outstanding Cell Cure ordinary shares (see Note 10) and substantially all of the Cell Cure Convertible Notes issued by Cell Cure to shareholders other than BioTime based on the closing price of BioTime common shares on the NYSE American The purchase of the Cell Cure Convertible Notes from HBL was accounted for as an extinguishment of a convertible debt with a beneficial conversion feature under ASC 470-50-40, Debt – Modifications and Extinguishments In connection with the purchase of all of the outstanding Cell Cure Convertible Notes from HBL and in accordance with ASC 470-50-40, BioTime recorded a charge to equity of $3.1 million representing the intrinsic value of the conversion option of the Cell Cure Convertible Notes, and a $2.8 million noncash loss on debt extinguishment included in other income and expenses, net, during the year ended December 31, 2017. Shared Facilities and Service Agreements with Affiliates The receivables from affiliates shown on the condensed consolidated balance sheet as of December 31, 2017 primarily represents amounts owed to BioTime from OncoCyte under a Shared Facilities and Service Agreement (the “Shared Facilities Agreement”). Under the terms of the Shared Facilities Agreement, BioTime allows OncoCyte to use BioTime’s premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime also provides accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime also has provided OncoCyte with the services of laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises. BioTime charges OncoCyte a “Use Fee” for services provided and usage of BioTime facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates to OncoCyte costs incurred, including costs for services of BioTime employees and use of equipment, insurance, leased space, professional services, software licenses, supplies and utilities. The allocation of costs depends on key cost drivers, including actual documented use, square footage of facilities used, time spent, costs incurred by BioTime for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime. BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime elected not to charge this markup from the inception of the Shared Facilities Agreement through December 31, 2015. For allocated costs incurred on and after January 1, 2016, BioTime is charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services. The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through December 31, 2017, BioTime has not charged OncoCyte any interest. In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers to invoice OncoCyte directly. The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement is otherwise terminated under another provision of the agreement. As of December 31, 2017, BioTime has a $2.1 million receivable from OncoCyte included in receivable from affiliates, net, on account of Use Fees incurred by OncoCyte under the Shared Facilities Agreement. Since these amounts are due and payable within 30 days of being invoiced, the receivable is classified as a current asset. The remaining $0.2 million receivable from affiliate is due from Ascendance Biotechnology, Inc. (“Ascendance”), an equity method investee of AgeX and former investee of BioTime (see Note 10), net of allowance for doubtful accounts, for similar shared services performed by BioTime for Ascendance. BioTime has a similar Shared Facilities Agreement with Asterias and, as of 31, 2017, there was a net payable to Asterias of $33,000. As of December 31, 2016, BioTime had a receivable from Asterias of approximately $0.3 million BioTime accounts for receivables from affiliates, net of payables to affiliates, if any, for similar shared services and other transactions BioTime’s consolidated subsidiaries may enter into with nonconsolidated affiliates. BioTime and the affiliates record those receivables and payables on a net basis since BioTime and the affiliate have a legal right of offset of the receivable and the payable, intend to offset those receivables and payables, and settle the balances net by having the party that owes the other party pay the net balance owed. Other related party transactions In connection with the capitalization of AgeX as discussed in Note 10, Alfred D. Kingsley, the Chairman of BioTime’s Board of Directors, purchased 200,000 shares of AgeX common stock. The AgeX shares were sold at the same price of $2.00 per share and on the same terms as shares were sold to other investors in AgeX pursuant to a series of Stock Purchase Agreements of like tenor. Mr. Kingsley acquired an additional 421,500 AgeX shares valued at $2.00 per share from BioTime in exchange for 300,000 BioTime common shares owned by Mr. Kingsley valued at $2.81 per share. In connection with its exchange of AgeX shares for BioTime shares with Mr. Kingsley, BioTime sold 300,000 BioTime common shares to an unaffiliated and existing BioTime investor also for $2.81 per share (see Note 10). The BioTime common shares acquired from Mr. Kingsley were immediately retired as authorized but unissued shares. BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Shareholders' Equity	10. Shareholders’ Equity Preferred Shares BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. As of December 31, 2017, no shares of preferred stock were issued or outstanding. Common Shares BioTime is authorized to issue 150,000,000 common shares with no par value. As of December 31, 2017, BioTime had 126,865,634 issued and outstanding common shares. As of December 31, 2016, BioTime had 103,396,245 issued and 102,776,539 outstanding common shares. The difference of 619,706 common shares as of December 31, 2016 is attributed to shares held by BioTime subsidiaries which are accounted for as treasury stock on the consolidated balance sheet. On February 17, 2017, and in connection with the OncoCyte Deconsolidation, those treasury shares were considered to be issued and outstanding BioTime common shares. As of December 31, 2017, there are no outstanding shares of treasury stock. On October 17, 2017, BioTime completed a public offering of 11,057,693 common shares at a price of $2.60 per share, including the underwriters’ full exercise of their over-allotment option to purchase additional shares. The public offering generated net proceeds to BioTime of approximately $26.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by BioTime. On July 10, 2017, BioTime issued 4,924,542 common shares valued at $15.2 million to purchase outstanding Cell Cure Convertible Notes and additional Cell Cure ordinary shares from noncontrolling interests in Cell Cure as further described in Note 9 and Transactions with Noncontrolling Interests of Cell Cure On April 6, 2017, BioTime, entered into a Controlled Equity Offering SM Statement of Cash Flows – Other Presentation Matters BioTime will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cantor Fitzgerald with customary indemnification and contribution rights. The Sales Agreement may be terminated by Cantor Fitzgerald or BioTime at any time upon notice to the other party, or by Cantor Fitzgerald at any time in certain circumstances, including the occurrence of a material and adverse change in BioTime’s business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. On February 15, 2017, BioTime sold 7,453,704 common shares in an underwritten public offering. The offering price to the public was $2.70 per share and net proceeds to BioTime were approximately $18.5 million, after deducting underwriting discounts, commissions and expenses related to the financing. On June 16, 2016, BioTime sold 7,322,176 common shares in an underwritten public offering at a public offering price of $2.39 per share, for net proceeds of $16.4 million, after deducting underwriting discounts and commissions and other expenses. On July 5, 2016, BioTime issued an additional 1,098,326 common shares upon the full exercise of the over-allotment option by the underwriters for net proceeds of $2.2 million, after deducting underwriting discounts. Significant common share transactions during the year ended December 31, 2015 are as follows: ● In September 2015, BioTime raised $8.6 million through the sale of 2,607,401 common shares at an offering price of $3.29 to three of its shareholders. ● During October 2015, BioTime sold 6,530,612 common shares for $20.4 million in the aggregate to certain investment funds in Israel that hold shares of companies that are included within certain stock indexes of the TASE. The $3.13 purchase price per share was determined with reference to the closing price of BioTime common shares on the TASE on the date of sale. In addition, OncoCyte sold 246,356 BioTime common shares at the same price to one of the Israeli investment funds. ● In October 2015, BioTime sold 1,600,000 common shares to a shareholder for $5.1 million. The $3.19 price of price per share was the closing price of the common shares on the NYSE American on October 1, 2015, the last trading day before BioTime and the shareholder entered into a purchase agreement for the sale of the shares. ● On December 31, 2015, BioTime distributed 4.7 million shares of OncoCyte common stock to its shareholders, on a pro rata basis, accounted for as a dividend in kind. On this date, BioTime shareholders received one share of OncoCyte common stock for every twenty shares of BioTime common stock held. As a result of this distribution, BioTime recorded a reduction in the carrying value of its investment in OncoCyte with a corresponding increase to noncontrolling interests in OncoCyte in the amount of $712,000, representing the reduction in BioTime’s ownership in OncoCyte by 18.7% from 76.5% to 57.8%. BioTime continues to hold a controlling financial interest in OncoCyte. This distribution generated a taxable gain of approximately $7.4 million to BioTime, however BioTime had sufficient current year losses to offset the entire gain. BioTime Warrants BioTime has issued equity-classified warrants to purchase its common shares. Activity related to warrants in 2017, 2016, and 2015 is presented in the table below (in thousands, except price per share): Number of Warrant Shares Per Share Exercise Price Weighted Average Exercise Price Outstanding, January 1, 2015 9,195 $ 5.00 $ 5.00 Exercised in 2015 (4) 5.00 5.00 Warrant adjustment (1) 919 Outstanding, December 31, 2015 10,110 $ 4.55 $ 4.55 Expired in 2016 (715) 4.55 4.55 Outstanding, December 31, 2016 9,395 $ 4.55 $ 4.55 Expired in 2017 - Outstanding, December 31, 2017 (2) 9,395 $ 4.55 $ 4.55 (1) The number of shares issuable upon the exercise of the warrants was adjusted as a result of the distribution of OncoCyte common stock to BioTime shareholders during December 2015. (2) The 9,394,862 outstanding warrants will expire, if unexercised, beginning June 5, 2018 through September 30, 2018. Transactions with Noncontrolling Interests of Asterias and OncoCyte BioTime accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary by BioTime under the provisions of ASC 810-10-45-23 , The subsidiary financing transactions with noncontrolling interests in Asterias for $18.3 million, and OncoCyte for $4.0 million, reported in the consolidated statements of shareholders’ equity for the year ended December 31, 2016, represent this proportional transfer of carrying value to BioTime pertaining to investments in Asterias and OncoCyte common stock made by noncontrolling shareholders in which BioTime’s ownership was reduced, but not below 50%. Transactions with Noncontrolling Interests of Cell Cure On July 10, 2017, BioTime purchased all of the outstanding Cell Cure Convertible Notes and Cell Cure ordinary shares held by HBL , a former Cell Cure shareholder that owned 21.2% of the issued and outstanding Cell Cure ordinary shares and substantially all of the Cell Cure Convertible Notes issued by Cell Cure shareholders other than BioTime (see Note 9) million based on the closing price of BioTime common shares on the NYSE American to acquire the Cell Cure ordinary shares from HBL and Teva. Prior to the consummation of the transactions with HBL and Teva, BioTime held 62.5% of the issued and outstanding Cell Cure ordinary shares and upon the consummation of the transactions BioTime held 99.8%. Accordingly, BioTime recorded a corresponding charge to equity of $10.1 million and a proportional transfer of carrying value of $3.5 million for purchase of noncontrolling interests in Cell Cure, included in the consolidated statement of shareholders’ equity for the year ended December 31, 2017, in accordance with On July 10, 2017, as an inducement to HBL to sell their Cell Cure ordinary shares to BioTime, Cell Cure issued 24,566 warrants to HBL (the “HBL Warrants”) to purchase Cell Cure ordinary shares at an exercise price of $40.5359 per warrant share, payable in U.S. dollars, the same Cell Cure price per ordinary share paid by BioTime to each of HBL and Teva for the purchase of their Cell Cure ordinary shares as discussed above. No warrants were issued to Teva. The HBL Warrants are immediately exercisable and expire on the earliest of the lapse of 5 years from the issuance date or immediately prior to the closing of a Corporate Transaction or an initial public offering, as defined in the HBL Warrant Agreements. Since the exercise price is U.S. dollar-denominated and settlement is not expected to occur in the next twelve months, Cell Cure classified the HBL Warrant as a long-term liability in accordance with ASC 815, Derivatives and Hedging The fair value of the HBL Warrants at the time of issuance was determined by using the Black-Scholes-Merton option pricing model using the contractual term of the warrants. In applying this model, the fair value is determined by applying Level 3 inputs, as defined by ASC 820; these inputs are based on certain key assumptions including the fair value of the Cell Cure ordinary shares and the expected stock price volatility over the term of the warrants. The fair value of the Cell Cure ordinary shares is determined by Cell Cure's Board of Directors, which, among other methods, may include engaging valuation specialists to estimate the fair value or use recent transactions, if any or as applicable, as a reasonable approximation of fair value. BioTime determines the stock price volatility using historical prices of comparable public company common stock for a period equal to the remaining term of the warrants. The HBL Warrants are revalued each reporting period using the same methodology described above. Changes in any of the key assumptions used to value the HBL Warrants could materially impact the fair value of the warrants and BioTime's consolidated financial statements. For the year ended December 31, 2017, Cell Cure recorded a noncash expense of $555,000 included in general and administrative expenses. As of December 31, 2017, the HBL Warrants, valued at $535,000 were included in other long-term liabilities on the consolidated balance sheet. See Note 9 for the accounting of the purchase of the Cell Cure Convertible Notes from HBL. On October 4, 2017, a Cell Cure option holder exercised Cell Cure stock options to purchase 4,400 Cell Cure ordinary shares, reducing BioTime’s ownership from 99.8% to 98.8% of total issued and outstanding Cell Cure ordinary shares. Transactions with Noncontrolling Interests of AgeX Therapeutics, Inc. AgeX was incorporated in January 2017 for the purpose of acquiring and developing BioTime technology relating to cell immortality and regenerative biology by developing products for the treatment of aging and age-related diseases. Initial product development plans include: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are type II diabetes, cardiac ischemia, and cancer, respectively. On August 17, 2017, AgeX received its initial assets and cash from BioTime and certain investors. BioTime contributed certain assets and cash to AgeX in exchange for 28,800,000 shares of AgeX common stock pursuant to an Asset Contribution and Separation Agreement (the “Asset Contribution Agreement”). BioTime and AgeX also entered into a License Agreement pursuant to which BioTime licensed or sublicensed to AgeX, and AgeX granted to BioTime an option to license back, certain patent rights. Concurrently with the acquisition of assets from BioTime under the Asset Contribution Agreement, AgeX sold 4,950,000 shares of its common stock for $10.0 million in cash primarily to investors, which included the Chairman of BioTime’s Board of Directors (see Note 9). At the close of the financing, BioTime owned 85.4% of the issued and outstanding shares of AgeX common stock. The AgeX shares were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D and Regulation S thereunder. AgeX has agreed to use commercially reasonable efforts to register the shares of AgeX common stock issued to the AgeX investors for sale under the Securities Act. Asset Contribution Agreement Assets Contributed: Pursuant to the Asset Contribution Agreement, BioTime contributed to AgeX the following assets: ● Intellectual property and proprietary technology, including certain patents and patent applications and know-how that comprised BioTime’s “iTR” and adipose brown fat tissue technology; ● Approximately 95% of the outstanding shares of ReCyte Therapeutics common stock, which constituted all of the shares BioTime held prior to the contribution; ● Approximately 82% of the outstanding shares of LifeMap Sciences common stock, which constituted all of the shares BioTime held prior to the contribution; ● Approximately 44% of the outstanding shares of Ascendance Biotechnology, Inc., (“Ascendance”) which constituted all of the shares BioTime held prior to the contribution. ● $100,000 in cash; and ● Certain other assets and contracts related to the AgeX research and development programs. Assumption of Liabilities: AgeX agreed to assume all third-party obligations and liabilities related to the assets contributed and contracts assigned to AgeX or the operation of the AgeX related business. Other Matters: The Asset Contribution Agreement also sets forth other terms that govern certain aspects of BioTime’s ongoing relationship with AgeX if in the future BioTime determines to distribute its AgeX shares to BioTime shareholders. License Agreement Concurrently with the contribution of assets to AgeX under the Asset Contribution Agreement, BioTime and AgeX entered into a License Agreement pursuant to which BioTime has licensed to AgeX, with rights to sublicense, certain intellectual property, including patents and patent applications and know-how for use in the development, manufacture and commercialization of products or services for the prevention, treatment, amelioration, diagnosis or monitoring of all human and non-human animal diseases and conditions except for the field of medical products, devices and services for the reserved BioTime fields of orthopedic, ophthalmic and medical aesthetic uses. In addition, BioTime retained an option right to license, on terms to be negotiated, iTR patents in research, development, manufacturing and commercialization of treatments in the reserved BioTime fields. The licensed patents and know-how relate generally to (a) BioTime’s PureStem ® The BioTime patent rights licensed to AgeX are exclusive and worldwide except for existing third-party licenses, and for medical products, devices, and services related to tendon. AgeX additionally received an option to license certain BioTime retained patent rights outside of orthopedic indications unless a license grant would compete with a BioTime program or products in the retained BioTime field. The Asset Contribution Agreement transactions were completed between entities under common control and the assets contributed by BioTime to AgeX were transferred at historical carrying values with no gain or loss recognized in accordance with ASC 810-10-45-23. As a result, pursuant to the new cash investment made by the outside noncontrolling interests in AgeX, this transaction resulted in a $8.2 million proportional equity transfer, at carrying value, from noncontrolling interests in AgeX to BioTime recorded in consolidated shareholders’ equity for the year ended December 31, 2017 Transactions with Noncontrolling Interests of Other Subsidiaries On June 6, 2017, BioTime increased its ownership in LifeMap Sciences from 78% to 82% and obtained a direct 100% ownership interest in LifeMap Solutions, of which 78% was previously indirectly owned by BioTime through LifeMap Sciences, for settlement and cancellation of certain intercompany debt owed by LifeMap Sciences. In 2017, certain OrthoCyte option holders exercised OrthoCyte stock options to purchase 51,000 shares of OrthoCyte common stock reducing BioTime’s ownership from 100% to 99.8% of total issued and outstanding shares of OrthoCyte common stock. BioTime recorded a $5.5 million net proportional equity transfer, at carrying values, from noncontrolling interests in these subsidiaries to BioTime included in consolidated shareholders’ equity for the year ended December 31, 2017, in accordance with

Stock Option Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plans	11. Stock Option Plans During 2002, BioTime adopted the 2002 Employee Stock Option Plan (the “2002 Plan”), which was amended in 2004, 2007, and 2009 to reserve additional common shares for issuance under options or restricted stock awards granted to eligible persons. The 2002 Plan expired during September 2012 and no additional grants of options or awards of restricted stock may be made under the 2002 Plan. During December 2012, BioTime’s Board of Directors approved the 2012 Equity Incentive Plan (the “2012 Plan”), which was amended during 2017, under which BioTime has reserved 16,000,000 common shares for the grant of stock options or the sale of restricted stock or other equity awards. No options may be granted under the 2012 Plan more than ten years after the date upon which the 2012 Plan was adopted by the Board of Directors, and no options granted under the 2012 Plan may be exercised after the expiration of ten years from the date of grant. Under the 2012 Plan, options to purchase common shares may be granted to employees, directors and certain consultants at prices not less than the fair market value at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee of the Board of Directors. The 2012 Plan also permits BioTime to award restricted stock for services rendered or to sell common shares to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events under a restricted stock award agreement. BioTime may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. BioTime may also grant stock appreciation rights (“SARs”) and hypothetical units issued with reference to BioTime common shares (“Restricted Stock Units”) under the Plan. An SAR is the right to receive, upon exercise, an amount payable in cash or shares or a combination of cash and shares, as determined by the Board of Directors or the Compensation Committee, equal to the number of shares subject to the SAR that is being exercised multiplied by the excess of (a) the fair market value of a BioTime common share on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement. The terms and conditions of a grant of Restricted Stock Units will be determined by the Board of Directors or Compensation Committee. No shares of stock will be issued at the time a Restricted Stock Unit is granted, and BioTime will not be required to set aside a fund for the payment of any such award. A recipient of Restricted Stock Units will have no voting rights with respect to the Restricted Stock Units. Upon the expiration of the restrictions applicable to a Restricted Stock Unit, BioTime will either issue to the recipient, without charge, one common share per Restricted Stock Unit or cash in an amount equal to the fair market value of one common share. The following table summarizes consolidated stock-based compensation expense, including equity awards by privately-held consolidated subsidiaries, related to stock options and other equity awards for the years ended December 31, 2017, 2016, and 2015, which was allocated as follows (in thousands): Year Ended December 31, 2017 2016 2015 Research and development $ 932 $ 2,608 $ 3,267 General and administrative 3,000 5,343 7,783 Total stock-based compensation expense $ 3,932 $ 7,951 $ 11,050 As of December 31, 2017, total unrecognized compensation costs related to unvested stock options under BioTime’s 2002 Plan and 2012 Plan was $3.7 million, approximately 2.44 years The weighted-average estimated fair value of stock options granted under BioTime’s 2002 Plan and 2012 Plan during the years ended December 31, 2017, 2016 and 2015 was $1.65, $1.69 and $2.13 per share respectively, using the Black-Scholes-Merton option pricing model with the following weighted-average assumptions: Year Ended December 31, 2017 2016 2015 Expected life (in years) 5.55 5.83 5.62 Risk-free interest rates 1.83% 1.45% 1.70% Volatility 58.76% 61.24% 65.82% Dividend yield -% -% -% General Option Information A summary of all equity award activity under BioTime’s 2002 Plan and 2012 Plan for the years ended December 31, 2017, 2016 and 2015 is as follows (in thousands except weighted average exercise price): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price January 1, 2015 668 3,974 - $ 4.04 Increase in option pool 6,000 - - Granted under 2012 Plan (1,650) 1,650 - 3.72 Exercised - (156) - 4.00 Forfeited/cancelled/expired under 2002 Plan - (35) - 6.72 Forfeited/cancelled/expired under 2012 Plan 239 (239) - 3.82 December 31, 2015 5,257 5,194 - $ 3.93 Granted under 2012 Plan (2,315) 2,315 - 3.03 RSUs (200) - 100 - Common stock issued to consultant in lieu of cash (28) - - - Common stock issued to employee for bonuses in lieu of cash (135) - - - Forfeited/cancelled/expired under 2002 Plan - (236) - 5.17 Forfeited/cancelled/expired under 2012 Plan 315 (315) - 3.77 December 31, 2016 2,894 6,958 100 $ 3.60 Increase to option pool 6,000 - Temporary restriction by Board on available pool (1) (5,000) - Granted under 2012 Plan (1,954) 1,954 3.04 Exercised - (9) 2.66 Forfeited/cancelled/expired under 2012 Plan 545 (860) 4.43 RSU vesting - - (38) December 31, 2017 2,485 8,043 62 $ 3.38 (1) On October 13, 2017, BioTime’s Board of Directors determined to temporarily set a limit on shares available for grants of share-based awards pursuant to the 2012 Plan. While that limit remains in place, BioTime will not grant share-based awards for more than a total of approximately 2.5 million of the common shares remaining available for awards under the 2012 Plan. During the year ended December 31, 2016, BioTime issued 81,603 immediately vested common shares in lieu of cash under the 2012 Plan. Those shares are not RSUs but are included in the reduction of approximately 163,000 aggregate shares from the total pool of shares available for grant in the table above. Common shares issued and RSUs granted from the 2012 Plan reduce the shares available for grant by two shares for each common share issued or RSU granted. No such grants were made in 2017. Additional information regarding options outstanding under BioTime’s 2002 Plan and 2012 Plan as of December 31, 2017 is as follows (in thousands except exercise prices and weighted average exercise price): Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $2.52 - $3.96 6,883 7.23 $ 3.24 3,190 $ 3.35 $4.02 - $4.95 1,150 3.17 $ 4.22 1,048 $ 4.22 $5.02 - $8.58 10 0.20 $ 32.62 10 $ 7.47 $2.52 - $8.58 8,043 6.64 $ 3.38 4,248 $ 3.57

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Alameda Lease On December 10, 2015, BioTime entered into a lease for approximately 30,795 square feet of rentable space in two buildings located in an office park in Alameda, California (the “Alameda Lease”). The term of the Alameda Lease is seven years and BioTime has an option to renew the term for an additional five years. BioTime moved into the facility and the term of the Alameda Lease commenced effective February 1, 2016. The landlord provided BioTime with an initial tenant improvement allowance of $1.4 million that was applied to the construction of improvements of the leased premises, primarily for the research and development facilities. BioTime utilized the tenant improvement allowance to complete the leasehold improvements as of June 1, 2016 (see Note 6). The lease liability payments are included in the base rent payments to the landlord and the $1.2 million due to the landlord as of December 31, 2017, will be amortized using the effective interest method over the lease term. Base rent under the Alameda Lease commenced on February 1, 2016 at $64,670 per month, and will increase by approximately 3% annually on every February 1 thereafter during the lease term. The lease payments allocated to the landlord liability are amortized as debt service on that liability over the lease term. In addition to base rent, BioTime will pay a pro rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlord’s operating expenses, over the amounts of those expenses incurred by the landlord during 2017. As security for the performance of its obligations under the Alameda Lease, BioTime provided the landlord with an initial security deposit of approximately $847,000, which will be reduced by $423,000 after the first twenty-four months of the lease term, and further reduced by an additional $346,000 after the first thirty-six months of the lease term, by applying those amounts to future rent payment obligations under the lease, if BioTime is not in default under the Lease. On February 1, 2018, the landlord reduced the security deposit by $423,000 pursuant to the lease agreement. New York Leased Office Space BioTime also currently pays $5,050 per month for the use of office space in New York City, which is made available to BioTime by one of its directors at his cost for use in conducting meetings and other business affairs. Cell Cure Lease Cell Cure has leased 1,128 square meters (approximately 12,142 square feet) of office and laboratory space in Jerusalem, Israel under a lease that expires between May 30, 2019 and December 31, 2020, with two additional options to extend the lease for 5 years each. Base monthly rent is NIS 63,402 (approximately US $18,247 per month using the December 31, 2017 exchange rate). In addition to base rent, Cell Cure pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located. As further disclosed in Note 17, on January 28, 2018, Cell Cure entered into another lease agreement with its current landlord. Annual Rent Expense and Future Minimum Lease Payments Rent expense totaled $1.1 million, $1.5 million, and $2.1 million for the years ended December 31, 2017, 2016, and 2015, respectively, included in the consolidated statements of operations. Future minimum annual lease payments under the various operating leases, including the Alameda Lease and the landlord lease liability, Cell Cure lease noted above, and capital leases, for the years ending after December 31, 2017 are as follows (in thousands): Year Ending December 31, Minimum Operating Lease Payments Capital Lease Payments 2018 $ 1,266 $ 31 2019 1,100 37 2020 1,030 37 2021 918 37 2022 946 37 Thereafter 86 16 Total minimum lease payments $ 5,346 $ 195 Less amounts representing interest (44) Present value of net minimum lease payments $ 151 Litigation – General BioTime will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When BioTime is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, BioTime will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, BioTime discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. BioTime is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts BioTime has entered into employment agreements with certain executive officers. Under the provisions of the agreements, BioTime may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations. Indemnification In the normal course of business, BioTime may provide indemnifications of varying scope under BioTime’s agreements with other companies or consultants, typically BioTime’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, BioTime will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of BioTime’s products and services. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to BioTime products and services. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments BioTime could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, BioTime has not been subject to any claims or demands for indemnification. BioTime also maintains various liability insurance policies that limit BioTime’s financial exposure. As a result, BioTime believes the fair value of these indemnification agreements is minimal. Accordingly, BioTime has not recorded any liabilities for these agreements as of December 31, 2017 and 2016. Second Amended and Restated License Agreement On June 15, 2017, Cell Cure entered into a Second Amended and Restated License Agreement (the “License Agreement”) with Hadasit Medical Research Services and Development Ltd. (“Hadasit”), the commercial arm and a wholly-owned subsidiary of Hadassah Medical Organization. Pursuant to the License Agreement, Hadasit granted Cell Cure an exclusive, worldwide, royalty bearing license (with the right to grant sublicenses) in its intellectual property portfolio of materials and technology related to human stem cell derived photoreceptor cells and retinal pigment epithelial cells (the “Licensed IP”), to use, commercialize and exploit any part thereof, in any manner whatsoever in the fields of the development and exploitation of (i) human stem cell derived photoreceptor cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders, and (ii) human stem cell derived retinal pigment epithelial cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders. As consideration for the Licensed IP, Cell Cure will pay a small one-time lump sum payment, a royalty in the mid single digits of net sales from sales of Licensed IP by any invoicing entity, and . In addition, Cell Cure will pay Hadasit an annual minimal non-refundable royalty, which will become due and payable the first January 1 following the completion of services to Cell Cure by a research laboratory. Cell Cure agreed to pay Hadasit non-refundable milestone payments upon the recruitment of the first patient for the first Phase IIB clinical trial, upon the enrollment of the first patient in the first Phase III clinical trials, upon delivery of the report for the first Phase III clinical trials, upon the receipt of an NDA or marketing approval in the European Union, whichever is the first to occur, and upon the first commercial sale in the United States or European Union, whichever is the first to occur. Such milestones, in the aggregate, may be up to $3.5 million. As of December 31, 2017, Cell Cure had not accrued any milestone payments under the License Agreement. The License Agreement terminates upon the expiration of Cell Cure’s obligation to pay royalties for all licensed products, unless earlier terminated. In addition, the License Agreement may be terminated by (i) Hadasit if, among other reasons, Cell Cure fails to continue the clinical development of the Licensed IP or fails to take actions to commercialize or sell the Licensed IP over any consecutive 12 month period, and (ii) by either party for (a) a material breach which remains uncured following a cure period, or (b) the granting of a winding-up order in respect of the other party, or upon an order being granted against the other party for the appointment of a receiver or a liquidator in respect of a substantial portion of such other party’s assets. The License Agreement also contains mutual confidentiality obligations of Cell Cure and Hadasit, and indemnification obligations of Cell Cure. Royalty obligations and license fees BioTime and its subsidiaries or affiliates are parties to certain licensing agreements with research institutions, universities and other parties for the rights to use those licenses and other intellectual property in conducting research and development activities. These licensing agreements provide for the payment of royalties by BioTime or the applicable party to the agreement on future product sales, if any. In addition, in order to maintain these licenses and other rights during the product development, BioTime or the applicable party to the contract must comply with various conditions including the payment of patent related costs and annual minimum maintenance fees. Annual minimum maintenance fees are approximately $135,000 to $150,000 per year. The research and development risk for these products is significant. License fees and related expenses under these agreements were $221,000, $180,000 and $282,000 for the years ended December 31, 2017, 2016 and 2015, respectively. Grants BioTime accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements Under the terms of the grant agreement between Cell Cure and Israel Innovation Authority (“IIA”) (formerly the Office of the Chief Scientist of Israel) of the Ministry of Economy and Industry, for the development of OpRegen ® OpRegen ® Accordingly, pursuant to ASC 730-20, the Cell Cure grant is considered a contract to perform research and development services for others and grant revenue is recognized as the related research and development expenses are incurred. Israeli law pertaining to such government grants contain various conditions, including substantial penalties and restrictions on the transfer of intellectual property, or the manufacture, or both, of products developed under the grant outside of Israel, as defined by the IIA.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes U.S. Federal Income Tax Reform On December 22, 2017, in response to the enactment of the 2017 Tax Act (see Note 2), the SEC staff issued SAB 118 that allows BioTime to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. BioTime is currently analyzing the 2017 Tax Act, and in certain areas, has made reasonable estimates of the effects on its consolidated financial statements and tax disclosures, including the amount of the repatriation tax and changes to BioTime’s existing deferred tax balances, for the year ended December 31, 2017. The repatriation tax is based primarily on LifeMap Sciences Ltd, an Israeli subsidiary of LifeMap Sciences, accumulated foreign earnings and profits that BioTime previously excluded from U.S. income taxes. As a result, LifeMap Sciences included $227,000 in foreign earnings in federal income for the current year. The federal taxable income was offset by the LifeMap Sciences’ net operating loss carryforwards resulting in no federal income tax due. In addition, BioTime remeasured certain deferred tax assets and liabilities based on the enacted tax rate at which they are expected to reverse in the future. The estimated tax effected amount related to the remeasurement of these balances was a reduction of BioTime’s net deferred tax assets by $8.9 million with a corresponding decrease in the valuation allowance by the same amount, recognized as of December 31, 2017, as discussed below. BioTime considers the key estimates on the repatriation tax, net deferred tax remeasurement and the impact on unrealized tax benefits, if any, to be incomplete due to its continuing analysis of final year-end data and tax positions. BioTime’s completion of this analysis could affect the measurement of these balances and give rise to new deferred tax assets and liabilities. Since the 2017 Tax Act was passed late in the fourth quarter of 2017, and further guidance and accounting interpretation is expected over the next twelve months, BioTime’s review is not complete and management expects to complete its analysis within the measurement period provided by SAB 118. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of December 31, 2017, the federal portion of the deferred tax assets and liabilities for 2017 were re-rated from 34 percent to 21 percent pursuant to the 2017 Tax Act. The primary components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows (in thousands): Deferred tax assets/(liabilities): 2017 2016 Net operating loss carryforwards $ 55,608 $ 78,116 Research and development and other credits 6,548 7,645 Patents and licenses 910 (67) Equity method investments at fair value (23,946) (40,258) Stock options 713 1,529 Other, net 812 2,248 Total 40,645 49,213 Valuation allowance (40,645) (49,213) Net deferred tax assets $ - $ - Income taxes differed from the amounts computed by applying the current U.S. federal income tax rate of 34% to pretax losses from operations as a result of the following: Year Ended December 31, 2017 2016 2015 Computed tax benefit at federal statutory rate 34% 34% 34% Research and development and other credits 2% (3%) 2% Re-rate of federal net deferred tax assets (38%) - - Permanent differences (8%) 2% (4%) Change in valuation allowance (32%) (63%) (34%) Establish deferred tax liability for OncoCyte shares at deconsolidation 17% - - State tax benefit, net of effect on federal income taxes 27% 24% 10% Foreign rate differential (2%) 6% (1%) -% -% 7% As of December 31, 2017, BioTime has gross net operating loss carryforwards of approximately $162.6 million for federal purposes. Of this amount, $17.6 million is attributable to LifeMap Sciences, which includes LifeMap Solutions, as LifeMap Sciences files a separate federal income tax return and their respective net operating loss carryforwards may not be used to offset the taxable income of BioTime. As of December 31, 2017, BioTime’s subsidiaries have foreign gross net operating loss carryforwards of approximately $65.2 million which carryforward indefinitely. As of December 31, 2017, BioTime has net operating losses of $95.0 million for state tax purposes. Historically, both LifeMap Sciences and OncoCyte have been included in the combined California tax return with BioTime. As a result of the OncoCyte Deconsolidation on February 17, 2017, (see Notes 3 and 4), OncoCyte will file a separate California return for tax year 2017. Accordingly, the California net operating loss carryforwards attributable to OncoCyte will not be available to BioTime or LifeMap Sciences. The federal and state net operating losses expire in varying amounts between 2018 and 2036. As of December 31, 2017, BioTime has research tax credit carryforwards for federal and state tax purposes of $3.3 million and $3.3 million, respectively. The federal tax credits expire between 2018 and 2036, while the state tax credits have no expiration date. Although the OncoCyte Deconsolidation on February 17, 2017 was not a taxable transaction to BioTime and did not result in a tax payment obligation, the $71.7 million unrealized gain on the OncoCyte Deconsolidation generated a deferred tax liability that was fully offset by BioTime’s net operating losses. Subsequent to the OncoCyte Deconsolidation, an unrealized loss of $2.9 million was recorded on the OncoCyte shares during the year ended December 31, 2017, which was fully offset by a corresponding increase in BioTime’s valuation allowance. Similarly, the Asterias Deconsolidation on May 13, 2016 was not a taxable transaction to BioTime and did not result in a tax payment obligation, the $49.0 million gain on the Asterias Deconsolidation generated a deferred tax liability that was fully offset by BioTime’s net operating losses. Subsequent to the Asterias Deconsolidation, an unrealized gain of $34.3 million was recorded on the Asterias shares during the year ended December 31, 2016, which was fully offset by available net operating losses and the corresponding release of BioTime’s valuation allowance on deferred tax assets. An unrealized loss of $51.1 million was recorded on the Asterias shares during the year ended December 31, 2017 . In connection with the deconsolidation of OncoCyte and Asterias (see Note 3), the market value of the respective shares BioTime holds creates a deferred tax liability to BioTime based on the closing price of the security, less the tax basis of the security BioTime has in such shares. The deferred tax liability generated by OncoCyte and Asterias shares that BioTime holds as of December 31, 2017, is a source of future taxable income to BioTime, as prescribed by ASC 740-10-30-17, that will more likely than not result in the realization of its deferred tax assets to the extent of those deferred tax liabilities. This deferred tax liability is determined based on the closing price of those securities as of December 31, 2017. On June 6, 2017, BioTime and LifeMap Sciences entered into a Debt Conversion Agreement whereby BioTime acquired additional stock in LifeMap Sciences (see Note 10) and other assets, including intellectual property in exchange for intercompany indebtedness of approximately $8.7 million owed to BioTime. This transaction had no financial reporting impact, except for transactions between noncontrolling interests of LifeMap Sciences discussed in Note 10. BioTime and LifeMap Sciences recorded the tax effect of the transactions in equity instead of the tax provision in accordance with ASC 740-20-45-11(g), which requires that the tax effects of all changes in tax bases of assets and liabilities caused by transactions among or with shareholders be included in equity. In connection with the June 2017 transactions, LifeMap Sciences utilized approximately $3.3 million in net operating loss carryforwards with a corresponding release of the valuation allowance recorded through equity in accordance with ASC 740-20-45-11(g). For income tax purposes, the purchase by BioTime of LifeMap Sciences’ intellectual property and other assets resulted in a taxable gain to LifeMap Sciences of $3.7 million for the year ended December 31, 2017. Although LifeMap Sciences had sufficient current year operating losses and regular net operating loss carryforwards to offset the entire gain, it incurred a federal alternative minimum tax payable of $22,000 as of December 31, 2017. As previously noted under the 2017 Tax Act, corporations are no longer subject to the AMT, effective for taxable years beginning after December 31, 2017. To the extent a company has an AMT credit from a prior year, the company can carry the credit forward to offset regular tax. To the extent the company does not have a federal tax liability, a portion of the AMT credit is refundable each year starting in 2018, with any remaining balance fully refundable in 2021. As LifeMap Sciences will ultimately receive a full refund of the current AMT payable, fully offsetting the current provision, there is no tax provision or benefit recorded for the year ended December 31, 2017. A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. BioTime established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by its subsidiaries. No tax provision or benefit was recorded for income taxes for the year ended December 31, 2016. A deferred income tax benefit of $4.5 million was recorded for the year ended December 31, 2015, of which $4.8 million was related to the federal benefit and $290,000 was related to state tax expense. Other Income Tax Matters Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by net operating loss (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. As of December 31, 2017, no such change in control pursuant to Section 382 had occurred. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2013. Although the statute is closed for purposes of assessing additional income and tax in these years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore, the statute should be considered open as it relates to the net operating loss and credit carryforwards used in open years. BioTime may be subject to potential examination by U.S. federal, U.S. states or foreign jurisdiction authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. BioTime’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. BioTime’s practice is to recognize interest and penalties related to income tax matters in tax expense. As of December 31, 2017 and 2016, BioTime has no accrued interest and penalties.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment Information	14. Segment Information BioTime’s executive management team, as a group, represents the entity’s chief operating decision makers. BioTime’s executive management team views BioTime’s operations as one segment that includes, the research and development of therapeutic products for retinal, orthopedics, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to BioTime’s sole operating segment.

Enterprise-Wide Disclosures

Enterprise-Wide Disclosures	12 Months Ended
	Dec. 31, 2017
Enterprise-wide Disclosures [Abstract]
Enterprise-Wide Disclosures	15. Enterprise-Wide Disclosures Geographic Area Information Total revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the customer, licensee or grantor (in thousands): Year Ended December 31, Geographic Area 2017 2016 2015 United States $ 1,651 $ 4,497 $ 5,976 Foreign (1) 1,807 1,426 1,060 Total revenues $ 3,458 $ 5,923 $ 7,036 (1) Foreign revenues are primarily earned in Israel. The composition of BioTime’s long-lived assets, consisting of property, plant and equipment, net, between those in the United States and in foreign countries, as of December 31, 2017 and 2016, is set forth below (in thousands): 2017 (1) 2016 (2) Domestic $ 2,746 $ 3,418 Foreign 2,787 2,111 Total $ 5,533 $ 5,529 (1) Reflects the effect of the OncoCyte Deconsolidation. (2) Reflects the effect of the Asterias Deconsolidation. Assets in foreign countries principally include laboratory equipment and leasehold improvements in Israel. Major Sources of Revenues The following table shows our major sources of revenues, as a percentage of total revenues, that were recognized during the years ended December 31, 2017, 2016, and 2015: Year Ended December 31, Sources of Revenues 2017 2016 2015 CIRM grant income (1) -% 38.0% 42.7% NIH grant income (2) 5.0% -% 6.5% IIA (formerly OCS) grant income (Cell Cure, Israel) 43.2% 24.0% 14.4% Subscriptions, advertising, licensing and other (various customers) (3) 49.4% 35.0% 29.4% Other 2.4% 3.0% 7.0% (1) Reflects income from grants to Asterias from the California Institute for Regenerative Medicine (CIRM) prior to the Asterias Deconsolidation (2) For 2017, reflects income from grants to BioTime from the National Institutes of Health (NIH). For 2015, reflects income from grants to ReCyte Therapeutics from the NIH. (3) For each of 2017 and 2016, one individual customer represents greater than 5% of total revenues. For 2015, no individual customer greater than 5% of total revenues. During 2017, BioTime received $1.4 million and recognized $1.2 million (net of $168,000 in royalty and commission fees included in cost of sales) in net subscription and advertisement revenues from LifeMap Sciences’ online database business primarily related to its GeneCards ®

Selected Quarterly Financial In

Selected Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Information (Unaudited)	16. Selected Quarterly Financial Information (UNAUDITED, in thousands, except per share data) BioTime has derived this data from the unaudited consolidated interim financial statements that, in BioTime’ s opinion, have been prepared on substantially the same basis as the audited consolidated financial statements contained herein and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited consolidated quarterly results should be read in conjunction with the consolidated financial statements and notes thereto included herein. The consolidated operating results in any quarter are not necessarily indicative of the consolidated results that may be expected for any future period. Year Ended December 31, 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Revenues, net $ 333 $ 376 $ 1,636 $ 945 Operating expenses 11,595 10,694 11,149 10,508 Loss from operations (11,262) (8,564) (9,513) (9,563) Net income (loss) attributable to BioTime 49,288 (11,651) 14,321 (71,934) Basic net income (loss) per share $ 0.46 $ (0.11) $ 0.12 $ (0.58) Year Ended December 31, 2016 Revenues, net $ 1,848 $ 1,171 $ 1,441 $ 1,103 Operating expenses 25,606 15,574 10,996 12,356 Loss from operations (23,758) (14,403) (9,555) (11,253) Net income (loss) attributable to BioTime (17,112) 24,549 31,199 (4,945) Basic net income (loss) per share $ (0.19) $ 0.26 $ 0.30 $ (0.05) Quarterly and year-to-date computations of net income (loss) per share amounts are calculated using the respective period weighted average shares outstanding. Therefore, the sum of the per share amounts for the quarters may not agree with the per share amounts for the year.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On January 28, 2018, Cell Cure entered into another lease agreement with its current landlord for an additional 934 square meters (approximately 10,054 square feet) of office space in the same facility in Jerusalem, Israel under a lease that expires on December 31, 2025, with two additional options to extend the lease for 5 years each (“the January 2018 Lease”). The January 2018 Lease will commence on April 1, 2018, and includes a leasehold improvement construction allowance of up to NIS 4,000,000 (approximately up to $1.2 million) from the landlord. The leasehold improvements are expected to be completed by September 30, 2018. Combined base rent and construction allowance payments, assuming the full allowance is utilized, for the January 2018 Lease will be NIS 93,470 per month (approximately $27,000 per month) beginning on October 1, 2018. On February 28, 2018, AgeX sold warrants to purchase 1,473,600 shares of common stock (the “AgeX Warrants”) for $0.50 cents per warrant for aggregate net cash proceeds to AgeX of $736,800. The AgeX Warrants are exercisable at $2.50 per share and expire the earliest to occur of (i) February 28, 2021, (ii) on or after January 31, 2019, after notice from AgeX, if the AgeX shares are publicly traded, the price of AgeX common stock exceeds $3.75 per share for 20 trading days (on a volume weighted average price basis, as defined), and (iii) a change of control, as defined in warrant agreement. If the AgeX shares are not publicly traded, the AgeX Warrants may be exercised only during the period commencing ten business days prior to the expiration date, as defined in the warrant agreement.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Going Concern Assessment	Going concern assessment –
Revenue Recognition	Revenue recognition Accounting Standards Codification Research and Development Arrangements
Cost of Sales	Cost of sales
Cash and Cash Equivalents	Cash and cash equivalents
Restricted Cash	Restricted cash
Trade Accounts and Grants Receivable, Net	Trade accounts and grants receivable, net –
Concentrations of Credit Risk	Concentrations of credit risk
Fair Value Measurements	Fair Value Measurements Fair Value Measurements and Disclosures ● Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value. In determining fair value, BioTime utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, BioTime has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds, shares BioTime holds in Asterias and OncoCyte and the available-for-sale securities, which are carried at fair value based on the applicable period-end quoted market prices as a Level 1 input. BioTime also has certain liability classified warrants issued by Cell Cure which are carried at fair value based on Level 3 inputs (see Note 10). The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.
Equity Method Accounting for Asterias and Oncocyte, at Fair Value	Equity method accounting for Asterias and OncoCyte, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations in other income and expenses, net. As further discussed in Notes 4 and 5, BioTime has elected to account for its Asterias and OncoCyte shares at fair value using the equity method of accounting because beginning on May 13, 2016 and February 17, 2017, the respective dates on which BioTime deconsolidated Asterias and OncoCyte, BioTime has not had control of Asterias and OncoCyte, as defined by GAAP since the applicable deconsolidation dates, but BioTime continues to exercise significant influence over Asterias and OncoCyte. Under the fair value method, the value of the shares of common stock BioTime holds in Asterias and OncoCyte is marked to market at each balance sheet date using the closing prices of Asterias and OncoCyte common stock on the NYSE American multiplied by the number of shares of Asterias and OncoCyte held by BioTime, with changes in the fair value of the Asterias and OncoCyte shares included in other income and expenses, net, in the consolidated statements of operations. The Asterias and OncoCyte shares are considered level 1 assets as defined by ASC 820.
Available-for-sale Securities in Foreign Investments	Available-for-sale securities in foreign investments Investments – Debt and Equity Securities
Property, Plant and Equipment, Net	Property, plant and equipment, net
Long-lived Intangible Assets	Long-lived intangible assets
Impairment of Long-lived Assets	Impairment of long-lived assets –
Treasury Stock	Treasury stock –
Accounting for Warrants	Accounting for warrants – Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock
Investments in Common Stock of Privately Held Companies	Investments in Common Stock of Privately Held Companies – Investments – Equity Method and Joint Ventures BioTime initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on BioTime’s share of earnings or losses from the investment included in other income or expenses, net, on the consolidated statements of operations. The equity method investment balance is shown in noncurrent assets on the consolidated balance sheets. BioTime reviews investments accounted for under the equity method for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be fully recoverable. If a determination is made that an “other-than-temporary” impairment exists, BioTime writes down its investment to fair value. Based on an evaluation and continuing losses and negative cash flows generated from the Ascendance investment, including uncertainty as to Ascendance’s ability to raise sufficient financing, BioTime determined that an other-than-temporary impairment existed on its equity method investment in Ascendance as of December 31, 2016, and BioTime wrote down the entire remaining $3.5 million carrying value of that investment included in other income and expenses, net.
Transactions with Noncontrolling Interests of Subsidiaries	Transactions with Noncontrolling Interests of Subsidiaries – 810-10-45-23, Consolidation Other Presentation Matters,
Research and Development	Research and development –
General and Administrative	General and administrative stock exchange-related costs, depreciation expense, marketing costs, and other miscellaneous expenses which are allocated to general and administrative expense
Foreign Currency Translation and Other Comprehensive Loss, Foreign Currency Transaction Gains and Losses	Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses – For transactions denominated in other than the functional currency of BioTime or its subsidiaries, BioTime recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The majority of BioTime’s foreign currency transaction gains and losses are generated by Cell Cure’s intercompany debt due to BioTime (see Note 9), which are U.S. dollar-denominated, while Cell Cure’s functional currency is NIS. Accordingly, foreign currency remeasurement gains and losses related to this debt are included in other income and expenses, net.
Income Taxes	Income taxes – BioTime accounts for income taxes in accordance with ASC 740, Income Taxes On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (“AMT”), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (“NOLs”) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer’s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax “deemed repatriation” on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 13). On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows BioTime to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 13).
Stock-based Compensation	Stock-based compensation – orfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09. Based on the nature and timing of grants, straight line expense attribution of stock-based compensation for the entire award and the relatively low forfeiture rates on BioTime’s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not material to the consolidated financial statements Certain of BioTime’s privately-held consolidated subsidiaries have their own share-based compensation plans. For share-based compensation awards granted by those privately-held consolidated subsidiaries under their respective equity plans, BioTime determines the expected stock price volatility using historical prices of comparable public company common stock for a period equal to the expected term of the options. The expected term of privately-held subsidiary options is based upon the “simplified method” provided under Staff Accounting Bulletin, Topic 14 Although the fair value of employee stock options is determined in accordance with FASB guidance, changes in the assumptions can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.
Basic and Diluted Net Income (Loss) Per Share Attributable to Common Shareholders	Basic and diluted net income (loss) per share attributable to common shareholders For the year ended December 31, 2016, the primary components of weighted average shares of potentially dilutive common shares used to compute diluted net income per common share were approximately 2,030,000 BioTime common shares held by Asterias and OncoCyte (see Note 10), and approximately 206,000 restricted stock units and outstanding stock options. For the years ended December 31, 2017 and 2015, b The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Year Ended December 31, 2017 2016 2015 Stock options 7,983 6,852 5,194 Warrants 9,395 9,395 10,109 Treasury stock 81 - 4,472
Adoption of ASU 2016-09, Improvements to Employee Share-Based Payment Accounting	Adoption of ASU 2016-09 , Improvements to Employee Share-Based Payment Accounting Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In connection with the adoption of ASU 2016-09, BioTime changed its accounting policies, including how it accounts for excess tax benefits and deficiencies, if any, and forfeitures, as applicable. All excess tax benefits and tax deficiencies from stock based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. Prior to the adoption of ASU 2016-09, BioTime recognized excess tax benefits, if any, in additional paid-in capital only if the tax deduction reduced cash income taxes payable and, excess tax deficiencies were recognized as an offset to accumulated excess tax benefits, if any, on BioTime’s consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because BioTime had an insignificant number of stock option exercises during the year ended December 31, 2017, and because of BioTime’s full valuation allowance as of December 31, 2017 and 2016, the impact to BioTime’s consolidated statements of operations for any excess tax benefits or deficiencies was immaterial (see Note 13). Forfeitures are now accounted for as they occur instead of based on the number of awards that were expected to vest. Based on (i) the nature and timing of BioTime’s grants, straight line expense attribution of stock based compensation for the entire award, and (ii) the relatively low forfeiture rates on BioTime’s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not material to BioTime’s consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgments and estimates may be required in the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The evaluation of the impact of adoption of ASU 2014-09 (Topic 606) on existing contracts with customers is still in process; however, BioTime does not expect the adoption of the new guidance will have a material impact to its consolidated financial statements. In performing this evaluation, BioTime has identified certain changes to business processes and internal controls relating to contracts and disclosures that are needed upon the adoption of the new guidance. BioTime will adopt this new standard on January 1, 2018, and plans on using the modified retrospective transition method, which requires the application of the new standard only to those contracts that were not completed as of the adoption date. Upon adoption of ASU 2014-09 and, if necessary, BioTime will recognize the cumulative effect of adopting this guidance as an adjustment to the opening consolidated accumulated deficit balance as of January 1, 2018. BioTime will continue to monitor industry activities and any additional guidance provided by regulators, standards setters, or the accounting profession and adjust its assessment and implementation plans accordingly. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that reporting period. Early adoption is permitted. BioTime is currently evaluating the impact the adoption of ASU 2016-02 will have on its consolidated financial statements. On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (ASU 2016-01). Changes to the GAAP model primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Based on the current accounting for ,

Organization, Basis of Presen26

Organization, Basis of Presentation and Liquidity (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Biotime's Ownership of Outstanding Shares of Its Subsidiaries	The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2017. Subsidiary Field of Business BioTime Ownership Country Cell Cure Neurosciences Ltd. (“Cell Cure”) Products to treat age-related macular degeneration 98.8% (1) Israel ES Cell International Pte. Ltd. (“ESI”) Stem cell products for research, including clinical grade cell lines produced under cGMP 100% Singapore OrthoCyte Corporation (“OrthoCyte”) Developing bone grafting products for orthopedic diseases and injuries 99.8% USA AgeX Therapeutics, Inc. (“AgeX”) PureStem ® 85.4% USA ReCyte Therapeutics, Inc. (“ReCyte Therapeutics”) (2) Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity 94.8% USA LifeMap Sciences, Inc. (“LifeMap Sciences”) (2), (3) Biomedical, gene, disease, and stem cell databases and tools 81.7% USA (1) Includes shares owned by BioTime and ESI (2) ReCyte Therapeutics and LifeMap Sciences are subsidiaries of AgeX (3) LifeMap Sciences, Ltd. (Israel) is a wholly-owned subsidiary of LifeMap Sciences

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Year Ended December 31, 2017 2016 2015 Stock options 7,983 6,852 5,194 Warrants 9,395 9,395 10,109 Treasury stock 81 - 4,472

Equity Method Accounting for 28

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value (Tables)	12 Months Ended
	Dec. 31, 2017
OncoCyte Corporation [Member]
Schedule of Equity Method Investments [Line Items]
Schedule of Condensed Results of Operations and Condensed Balance Sheet Information	The condensed results of operations and condensed balance sheet information of OncoCyte are summarized below (in thousands): For the Period January 1, 2017 through (1) Condensed Statement of Operations (1) Research and development expense $ 798 General and administrative expense 377 Sales and marketing expense 213 Loss from operations (1,388) Net loss $ (1,392) (1) OncoCyte’s condensed results of operations for the period from January 1, 2017 through February 16, 2017, the date immediately preceding the OncoCyte Deconsolidation, for the year ended December 31, 2017, and for the years ended December 31, 2016 and 2015, shown in the table below, are included in the consolidated results of operations of BioTime for those respective periods, after intercompany eliminations, as applicable. The following table summarizes OncoCyte results of operations for the full years ended December 31, 2017, 2016 and 2015 (in thousands). Condensed Statements of Operations Year Ended December 31, 2017 Year Ended December 31, 2016 Year Ended December 31, 2015 Research and development expense $ 7,174 $ 5,677 $ 4,527 General and administrative expense 9,232 4,265 3,867 Sales and marketing expense 2,443 1,198 324 Loss from operations (18,849) (11,140) (8,718) Net loss $ (19,375) $ (11,168) $ (8,735) December 31, 2017 December 31, 2016 Condensed Balance Sheet information (2) Current assets $ 8,528 $ 12,696 Noncurrent assets 1,688 1,751 $ 10,216 $ 14,447 Current liabilities $ 4,454 $ 4,275 Noncurrent liabilities 1,359 310 Stockholders’ equity 4,403 9,862 $ 10,216 $ 14,447 (2) The condensed balance sheet information of OncoCyte as of December 31, 2017 and 2016, is provided for informational and comparative purposes only. OncoCyte was not included in BioTime’s consolidated balance sheet at December 31, 2017.

Equity Method Accounting for 29

Equity Method Accounting for Common Stock of Asterias, at Fair Value (Tables)	12 Months Ended
	Dec. 31, 2017
Asterias Biotherapeutics [Member]
Schedule of Equity Method Investments [Line Items]
Schedule of Condensed Results of Operations and Condensed Balance Sheet Information	The condensed results of operations and condensed balance sheet information of Asterias are summarized below (in thousands): For the Period January 1, 2016 through (1) Condensed Statement of Operations (1) Total revenue $ 2,354 Gross profit 2,301 Loss from operations (13,944) Net loss $ (13,113) (1) Asterias condensed results of operations for the period from January 1, 2016 through May 12, 2016, the date immediately preceding the Asterias Deconsolidation, for the year ended December 31, 2016, and for the year ended December 31, 2015, shown in the table below, are included in the consolidated results of operations of BioTime for the years ended December 31, 2016 and 2015, respectively, after intercompany eliminations, as applicable. The following table summarizes Asterias results of operations for the full years ended December 31, 2017, 2016 and 2015 (in thousands). Condensed Statements of Operations Year Ended December 31, 2017 Year Ended December 31, 2016 Year Ended December 31, 2015 Total revenue $ 4,042 $ 6,954 $ 3,582 Gross profit 3,877 6,826 3,314 Loss from operations (33,251) (34,123) (21,908) Net loss $ (28,372) $ (35,489) $ (15,003) December 31, 2017 December 31, 2016 Condensed Balance Sheet information (1) Current assets $ 22,716 $ 36,990 Noncurrent assets 20,376 24,020 $ 43,092 $ 61,010 Current liabilities $ 3,521 $ 6,535 Noncurrent liabilities 6,028 12,447 Stockholders’ equity 33,543 42,028 $ 43,092 $ 61,010 (1) The condensed balance sheet information of Asterias as of December 31, 2017 and 2016, is provided for informational and comparative purposes only and was not included in BioTime’s consolidated balance sheet as of December 31, 2017 and 2016 due to the Asterias Deconsolidation on May 13, 2016.

Property, Plant and Equipment30

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	At December 31, 2017 and 2016, property, plant and equipment were comprised of the following (in thousands): December 31, 2017 (1) 2016 (2) Equipment, furniture and fixtures $ 4,255 $ 4,718 Leasehold improvements 4,434 3,791 Accumulated depreciation and amortization (3,156) (2,980) Property and equipment, net $ 5,533 $ 5,529 (1) Reflects the effect of the OncoCyte Deconsolidation. (2) Reflects the effect of the Asterias Deconsolidation

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	At December 31, 2017 and 2016, intangible assets, primarily consisting of acquired patents and accumulated amortization were as follows (in thousands): December 31, 2017 (1) 2016 (2) Intangible assets $ 23,294 $ 25,703 Accumulated amortization (16,394) (15,497) Intangible assets, net $ 6,900 $ 10,206 (1) Reflects the effect of the OncoCyte Deconsolidation. (2) Reflects the effect of the Asterias Deconsolidation
Schedule of Intangible Assets Future Amortization Expense	Amortization of intangible assets for periods subsequent to December 31, 2017 is as follows (in thousands): Year Ended December 31, Amortization Expense 2018 $ 2,338 2019 2,328 2020 1,553 2021 517 2022 164 Total $ 6,900

Accounts Payable and Accrued 32

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	At December 31, 2017 and 2016, accounts payable and accrued liabilities consist of the following (in thousands): December 31, 2017 (1) 2016 (2) Accounts payable $ 938 $ 1,593 Accrued liabilities 2,368 3,212 Accrued compensation 2,275 1,904 Other current liabilities 137 435 Total $ 5,718 $ 7,144 (1) Reflects the effect of the OncoCyte Deconsolidation (2) Reflects the effect of the Asterias Deconsolidation.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Activity Related to Warrants	BioTime has issued equity-classified warrants to purchase its common shares. Activity related to warrants in 2017, 2016, and 2015 is presented in the table below (in thousands, except price per share): Number of Warrant Shares Per Share Exercise Price Weighted Average Exercise Price Outstanding, January 1, 2015 9,195 $ 5.00 $ 5.00 Exercised in 2015 (4) 5.00 5.00 Warrant adjustment (1) 919 Outstanding, December 31, 2015 10,110 $ 4.55 $ 4.55 Expired in 2016 (715) 4.55 4.55 Outstanding, December 31, 2016 9,395 $ 4.55 $ 4.55 Expired in 2017 - Outstanding, December 31, 2017 (2) 9,395 $ 4.55 $ 4.55 (1) The number of shares issuable upon the exercise of the warrants was adjusted as a result of the distribution of OncoCyte common stock to BioTime shareholders during December 2015. (2) The 9,394,862 outstanding warrants will expire, if unexercised, beginning June 5, 2018 through September 30, 2018.

Stock Option Plans (Tables)

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Based Compensation Expense	The following table summarizes consolidated stock-based compensation expense, including equity awards by privately-held consolidated subsidiaries, related to stock options and other equity awards for the years ended December 31, 2017, 2016, and 2015, which was allocated as follows (in thousands): Year Ended December 31, 2017 2016 2015 Research and development $ 932 $ 2,608 $ 3,267 General and administrative 3,000 5,343 7,783 Total stock-based compensation expense $ 3,932 $ 7,951 $ 11,050
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options	The weighted-average estimated fair value of stock options granted under BioTime’s 2002 Plan and 2012 Plan during the years ended December 31, 2017, 2016 and 2015 was $1.65, $1.69 and $2.13 per share respectively, using the Black-Scholes-Merton option pricing model with the following weighted-average assumptions: Year Ended December 31, 2017 2016 2015 Expected life (in years) 5.55 5.83 5.62 Risk-free interest rates 1.83% 1.45% 1.70% Volatility 58.76% 61.24% 65.82% Dividend yield -% -% -%
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity	A summary of all equity award activity under BioTime’s 2002 Plan and 2012 Plan for the years ended December 31, 2017, 2016 and 2015 is as follows (in thousands except weighted average exercise price): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price January 1, 2015 668 3,974 - $ 4.04 Increase in option pool 6,000 - - Granted under 2012 Plan (1,650) 1,650 - 3.72 Exercised - (156) - 4.00 Forfeited/cancelled/expired under 2002 Plan - (35) - 6.72 Forfeited/cancelled/expired under 2012 Plan 239 (239) - 3.82 December 31, 2015 5,257 5,194 - $ 3.93 Granted under 2012 Plan (2,315) 2,315 - 3.03 RSUs (200) - 100 - Common stock issued to consultant in lieu of cash (28) - - - Common stock issued to employee for bonuses in lieu of cash (135) - - - Forfeited/cancelled/expired under 2002 Plan - (236) - 5.17 Forfeited/cancelled/expired under 2012 Plan 315 (315) - 3.77 December 31, 2016 2,894 6,958 100 $ 3.60 Increase to option pool 6,000 - Temporary restriction by Board on available pool (1) (5,000) - Granted under 2012 Plan (1,954) 1,954 3.04 Exercised - (9) 2.66 Forfeited/cancelled/expired under 2012 Plan 545 (860) 4.43 RSU vesting - - (38) December 31, 2017 2,485 8,043 62 $ 3.38 (1) On October 13, 2017, BioTime’s Board of Directors determined to temporarily set a limit on shares available for grants of share-based awards pursuant to the 2012 Plan. While that limit remains in place, BioTime will not grant share-based awards for more than a total of approximately 2.5 million of the common shares remaining available for awards under the 2012 Plan.
Schedule of Options Outstanding and Exercisable Range of Exercise Prices	Additional information regarding options outstanding under BioTime’s 2002 Plan and 2012 Plan as of December 31, 2017 is as follows (in thousands except exercise prices and weighted average exercise price): Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $2.52 - $3.96 6,883 7.23 $ 3.24 3,190 $ 3.35 $4.02 - $4.95 1,150 3.17 $ 4.22 1,048 $ 4.22 $5.02 - $8.58 10 0.20 $ 32.62 10 $ 7.47 $2.52 - $8.58 8,043 6.64 $ 3.38 4,248 $ 3.57

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Operating and Capital Lease Payments	Future minimum annual lease payments under the various operating leases, including the Alameda Lease and the landlord lease liability, Cell Cure lease noted above, and capital leases, for the years ending after December 31, 2017 are as follows (in thousands): Year Ending December 31, Minimum Operating Lease Payments Capital Lease Payments 2018 $ 1,266 $ 31 2019 1,100 37 2020 1,030 37 2021 918 37 2022 946 37 Thereafter 86 16 Total minimum lease payments $ 5,346 $ 195 Less amounts representing interest (44) Present value of net minimum lease payments $ 151

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Deferred Tax Assets and Liabilities	The primary components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows (in thousands): Deferred tax assets/(liabilities): 2017 2016 Net operating loss carryforwards $ 55,608 $ 78,116 Research and development and other credits 6,548 7,645 Patents and licenses 910 (67) Equity method investments at fair value (23,946) (40,258) Stock options 713 1,529 Other, net 812 2,248 Total 40,645 49,213 Valuation allowance (40,645) (49,213) Net deferred tax assets $ - $ -
Schedule of Income Tax Rate Reconciliation	Income taxes differed from the amounts computed by applying the current U.S. federal income tax rate of 34% to pretax losses from operations as a result of the following: Year Ended December 31, 2017 2016 2015 Computed tax benefit at federal statutory rate 34% 34% 34% Research and development and other credits 2% (3%) 2% Re-rate of federal net deferred tax assets (38%) - - Permanent differences (8%) 2% (4%) Change in valuation allowance (32%) (63%) (34%) Establish deferred tax liability for OncoCyte shares at deconsolidation 17% - - State tax benefit, net of effect on federal income taxes 27% 24% 10% Foreign rate differential (2%) 6% (1%) -% -% 7%

Enterprise-Wide Disclosures (Ta

Enterprise-Wide Disclosures (Tables)	12 Months Ended
	Dec. 31, 2017
Enterprise-wide Disclosures [Abstract]
Schedule of Geographic Area Information	Total revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the customer, licensee or grantor (in thousands): Year Ended December 31, Geographic Area 2017 2016 2015 United States $ 1,651 $ 4,497 $ 5,976 Foreign (1) 1,807 1,426 1,060 Total revenues $ 3,458 $ 5,923 $ 7,036 (1) Foreign revenues are primarily earned in Israel. The composition of BioTime’s long-lived assets, consisting of property, plant and equipment, net, between those in the United States and in foreign countries, as of December 31, 2017 and 2016, is set forth below (in thousands): 2017 (1) 2016 (2) Domestic $ 2,746 $ 3,418 Foreign 2,787 2,111 Total $ 5,533 $ 5,529 (1) Reflects the effect of the OncoCyte Deconsolidation. (2) Reflects the effect of the Asterias Deconsolidation.
Schedule of Sources of Revenues	The following table shows our major sources of revenues, as a percentage of total revenues, that were recognized during the years ended December 31, 2017, 2016, and 2015: Year Ended December 31, Sources of Revenues 2017 2016 2015 CIRM grant income (1) -% 38.0% 42.7% NIH grant income (2) 5.0% -% 6.5% IIA (formerly OCS) grant income (Cell Cure, Israel) 43.2% 24.0% 14.4% Subscriptions, advertising, licensing and other (various customers) (3) 49.4% 35.0% 29.4% Other 2.4% 3.0% 7.0% (1) Reflects income from grants to Asterias from the California Institute for Regenerative Medicine (CIRM) prior to the Asterias Deconsolidation (2) For 2017, reflects income from grants to BioTime from the National Institutes of Health (NIH). For 2015, reflects income from grants to ReCyte Therapeutics from the NIH. (3) For each of 2017 and 2016, one individual customer represents greater than 5% of total revenues. For 2015, no individual customer greater than 5% of total revenues.

Selected Quarterly Financial 38

Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Selected Quarterly Financial Information	The consolidated operating results in any quarter are not necessarily indicative of the consolidated results that may be expected for any future period. Year Ended December 31, 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Revenues, net $ 333 $ 376 $ 1,636 $ 945 Operating expenses 11,595 10,694 11,149 10,508 Loss from operations (11,262) (8,564) (9,513) (9,563) Net income (loss) attributable to BioTime 49,288 (11,651) 14,321 (71,934) Basic net income (loss) per share $ 0.46 $ (0.11) $ 0.12 $ (0.58) Year Ended December 31, 2016 Revenues, net $ 1,848 $ 1,171 $ 1,441 $ 1,103 Operating expenses 25,606 15,574 10,996 12,356 Loss from operations (23,758) (14,403) (9,555) (11,253) Net income (loss) attributable to BioTime (17,112) 24,549 31,199 (4,945) Basic net income (loss) per share $ (0.19) $ 0.26 $ 0.30 $ (0.05)

Organization, Basis of Presen39

Organization, Basis of Presentation and Liquidity (Details Narrative) $ in Thousands	Aug. 17, 2017USD ($)	Feb. 17, 2017	May 13, 2016	Dec. 31, 2017USD ($)Sector	Jul. 10, 2017	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Number of platform technologies | Sector				2
Number of subsidiaries | Sector				2
Ownership percentage				20.00%	99.80%
Accumulated deficit				$ 216,297		$ 196,321
Working capital				35,700
Shareholders' equity				164,263		$ 130,508	$ 76,447	$ 62,723
Cash, cash equivalents and available for sale securities				38,200
AgeX Therapeutics, Inc [Member]
Proceeds from sale of common shares of subsidiary	$ 10,000
Ownership percentage	85.00%
OncoCyte [Member]
Description of ownership percentage		BioTime’s ownership of OncoCyte declined below 50% after certain OncoCyte investors acquired OncoCyte common stock by exercising OncoCyte stock purchase warrants
Asterias [Member]
Description of ownership percentage			BioTime BioTime’s percentage ownership in Asterias declined below 50% as a result of Asterias’ public offering of its common stock to raise capital for its operations
Asterias and OncoCyte [Member]
Common stock combined value				$ 117,200

Organization, Basis of Presen40

Organization, Basis of Presentation and Liquidity - Schedule of Biotime's Ownership of Outstanding Shares of Its Subsidiaries (Details)	Dec. 31, 2017
Israel | Cell Cure Neurosciences, Ltd. [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	98.80%	[1]
Singapore | ES Cell International Pte., Ltd. [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	100.00%
USA | OrthoCyte Corporation [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	99.80%
USA | AgeX Therapeutics, Inc. [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	85.40%
USA | ReCyte Therapeutics, Inc. [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	94.80%	[2]
USA | LifeMap Sciences, Inc. [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	81.70%	[2],[3]
[1]	Includes shares owned by BioTime and ESI
[2]	ReCyte Therapeutics and LifeMap Sciences are subsidiaries of AgeX
[3]	LifeMap Sciences, Ltd. (Israel) is a wholly-owned subsidiary of LifeMap Sciences

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jul. 10, 2017	Feb. 17, 2017
Money market funds, cash equivalent		$ 32,100	$ 16,800
Certificates deposit		847
Net trade receivable		139	344
Grants receivable		641	102
Allowance for doubtful accounts		$ 422	543
Intangible asset, useful life		10 years
Equity method ownership percentage		20.00%			99.80%
Write down of investment			3,500
Change in foreign currency translation		$ 668	$ (106)	$ (424)
U.S. Federal tax rates	21.00%	27.00%	24.00%	10.00%
Weighted average dilutive common shares used to compute diluted net income per common shares		114,476,000	99,553,000	79,711,000
Restricted Stock Units and Outstanding Stock Options [Member]
Weighted average dilutive common shares used to compute diluted net income per common shares			206,000
Asterias and OncoCyte [Member]
Weighted average dilutive common shares used to compute diluted net income per common shares			2,030,000
Minimum [Member]
Estimated useful life		3 years
Maximum [Member]
Estimated useful life		10 years
Equity method ownership percentage						50.00%
February 13, 2018 [Member] | Lease Agreement [Member]
Certificates deposit		$ 424

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount	7,983,000	6,852,000	5,194,000
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	9,395,000	9,395,000	10,109,000
Treasury Shares [Member]
Antidilutive securities excluded from computation of earnings per share, amount	81,000		4,472,000

Deconsolidation of OncoCyte a43

Deconsolidation of OncoCyte and Asterias (Details Narrative) - USD ($) $ in Thousands	Feb. 17, 2017	May 13, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jul. 10, 2017
Issuance of common stock to certain investors upon exercise of warrants	625,000
Equity method ownership percentage			20.00%			99.80%
Common shares, outstanding			126,866,000	102,776,000
Asterias Biotherapeutics [Member]
Number of shares sold		5,147,059
Warrants issued to purchase common stock		2,959,559
Number of units available through offerings		708,333
OncoCyte Corporation [Member]
Gain on deconsolidation			$ 71,697
Common shares, outstanding			14,700
Percentage of ownership interest outstanding after offering			46.70%
Asterias Biotherapeutics [Member]
Gain on deconsolidation				$ 49,048
Common shares, outstanding			21,700,000
Percentage of ownership interest outstanding after offering			40.20%
Maximum [Member]
Equity method ownership percentage	50.00%
Maximum [Member] | Asterias Biotherapeutics [Member]
Equity method ownership percentage				50.00%
Percentage of ownership interest outstanding after offering		48.70%

Equity Method Accounting for 44

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value (Details Narrative) - OncoCyte Corporation [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 17, 2017
Common stock at fair value				14,700,000
Fair value on investment	$ 68,200			$ 71,200
Price per share on NYSE American	$ 4.65			$ 4.85
Unrealized gains on equity method investment	$ 2,935

Equity Method Accounting for 45

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value - Schedule of Condensed Results of Operations and Condensed Balance Sheet Information (Details) - OncoCyte Corporation [Member] - USD ($) $ in Thousands		2 Months Ended		12 Months Ended
		Feb. 16, 2017	[1]	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and development expense		$ 798		$ 7,174	$ 5,677	$ 4,527
General and administrative expense		377		9,232	4,265	3,867
Sales and marketing expense		213		2,443	1,198	324
Loss from operations		(1,388)		(18,849)	(11,140)	(8,718)
Net loss		$ (1,392)		(19,375)	(11,168)	$ (8,735)
Current assets	[2]			8,528	12,696
Noncurrent assets	[2]			1,688	1,751
Total assets	[2]			10,216	14,447
Current liabilities	[2]			4,454	4,275
Noncurrent liabilities	[2]			1,359	310
Stockholders' equity	[2]			4,403	9,862
Total liabilities and stockholders' equity	[2]			$ 10,216	$ 14,447
[1]	OncoCyte’s condensed results of operations for the period from January 1, 2017 through February 16, 2017, the date immediately preceding the OncoCyte Deconsolidation, for the year ended December 31, 2017, and for the years ended December 31, 2016 and 2015, shown in the table below, are included in the consolidated results of operations of BioTime for those respective periods, after intercompany eliminations, as applicable.
[2]	The condensed balance sheet information of OncoCyte as of December 31, 2017 and 2016, is provided for informational and comparative purposes only. OncoCyte was not included in BioTime’s consolidated balance sheet at December 31, 2017.

Equity Method Accounting for 46

Equity Method Accounting for Common Stock of Asterias, at Fair Value (Details Narrative) - Asterias Biotherapeutics [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	May 13, 2016
Common stock, outstanding				21,700,000
Fair value on investment	$ 48,900	$ 100,000		$ 65,700
Price per share on NYSE American	$ 2.25	$ 4.60		$ 3.02
Unrealized gains on equity method investment	$ (51,107)	$ 34,361

Equity Method Accounting for 47

Equity Method Accounting for Common Stock of Asterias, at Fair Value - Schedule of Condensed Results of Operations and Condensed Balance Sheet Information (Details) - Asterias Biotherapeutics [Member] - USD ($) $ in Thousands		4 Months Ended		12 Months Ended
		May 12, 2016	[1]	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total revenue		$ 2,354		$ 4,042	$ 6,954	$ 3,582
Gross profit		2,301		3,877	6,826	3,314
Loss from operations		(13,944)		(33,251)	(34,123)	(21,908)
Net loss		$ (13,113)		(28,372)	(35,489)	$ (15,003)
Current assets	[2]			22,716	36,990
Noncurrent assets	[2]			20,376	24,020
Total assets	[2]			43,092	61,010
Current liabilities	[2]			3,521	6,535
Noncurrent liabilities	[2]			6,028	12,447
Stockholders' equity	[2]			33,543	42,028
Total liabilities and stockholders' equity	[2]			$ 43,092	$ 61,010
[1]	Asterias condensed results of operations for the period from January 1, 2016 through May 12, 2016, the date immediately preceding the Asterias Deconsolidation, for the year ended December 31, 2016, and for the year ended December 31, 2015, shown in the table below, are included in the consolidated results of operations of BioTime for the years ended December 31, 2016 and 2015, respectively, after intercompany eliminations, as applicable.
[2]	The condensed balance sheet information of Asterias as of December 31, 2017 and 2016, is provided for informational and comparative purposes only and was not included in BioTime’s consolidated balance sheet as of December 31, 2017 and 2016 due to the Asterias Deconsolidation on May 13, 2016.

Property, Plant and Equipment48

Property, Plant and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 01, 2016
Property plant and equipment	$ 151	$ 626
Depreciation and amortization expense	947	$ 1,180	$ 1,078
Leasehold improvements				$ 1,600
Nonreimbursement leasehold improvement from landlord	200
Maximum [Member]
Tenant improvement allowance under lease agreement	$ 1,400

Property, Plant and Equipment49

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	[1]	Dec. 31, 2016	[2]
Property, Plant and Equipment [Line Items]
Accumulated depreciation and amortization	$ (3,156)		$ (2,980)
Property, plant and equipment, net	5,533		5,529
Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	4,255		4,718
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 4,434		$ 3,791
[1]	Reflects the effect of the OncoCyte Deconsolidation.
[2]	Reflects the effect of the Asterias Deconsolidation

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets, useful life	10 years
Amortization of intangible assets	$ 2,349	$ 3,577	$ 5,256

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	[1]	Dec. 31, 2016	[2]
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets	$ 23,294		$ 25,703
Accumulated amortization	(16,394)		(15,497)
Intangible assets, net	$ 6,900		$ 10,206
[1]	Reflects the effect of the OncoCyte Deconsolidation.
[2]	Reflects the effect of the Asterias Deconsolidation

Intangible Assets, Net - Sche52

Intangible Assets, Net - Schedule of Intangible Assets Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2017		Dec. 31, 2016	[2]
Goodwill and Intangible Assets Disclosure [Abstract]
2,018	$ 2,338
2,019	2,328
2,020	1,553
2,021	517
2,022	164
Intangible assets, net	$ 6,900	[1]	$ 10,206
[1]	Reflects the effect of the OncoCyte Deconsolidation.
[2]	Reflects the effect of the Asterias Deconsolidation

Accounts Payable and Accrued 53

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	[1]	Dec. 31, 2016	[2]
Payables and Accruals [Abstract]
Accounts payable	$ 938		$ 1,593
Accrued liabilities	2,368		3,212
Accrued compensation	2,275		1,904
Other current liabilities	137		435
Total	$ 5,718		$ 7,144
[1]	Reflects the effect of the OncoCyte Deconsolidation.
[2]	Reflects the effect of the Asterias Deconsolidation

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Oct. 17, 2017USD ($)$ / sharesshares	Jul. 10, 2017USD ($)$ / sharesshares	Jul. 10, 2017USD ($)$ / sharesshares	Feb. 15, 2017USD ($)$ / sharesshares	Jul. 05, 2016USD ($)shares	Jun. 16, 2016USD ($)$ / sharesshares	Oct. 31, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2017USD ($)ft²$ / shares	Dec. 31, 2017USD ($)ft²$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Feb. 17, 2017$ / shares	May 13, 2016$ / shares
Carrying value of convertible notes											$ 1,032,000
Common shares issued value										45,068,000	18,606,000	$ 33,897,000
Intrinsic value of equity										3,100,000
Loss on debt extinguishment										$ 2,799,000
Markup rate on allocated costs										5.00%
Interest rate charged on unpaid and overdue invoices										15.00%
Receivables from related party									$ 2,100,000	$ 2,100,000
Rent per month										$ 5,050
Area of office space square feet | ft²									900	900
Alfred D. Kingsley [Member]
Common shares issued | shares										200,000
Stock price per share | $ / shares									$ 2	$ 2
Common stock shares converted | shares										300,000
Common stock shares converted price per share | $ / shares									2.81	$ 2.81
Common Stock [Member]
Common shares issued | shares	11,057,693		4,924,542	7,453,704	1,098,326	7,322,176	1,600,000	2,607,401		18,511,000	8,420,000	10,738,000
Common shares issued value	$ 26,700,000		$ 15,200,000	$ 18,500,000	$ 2,200,000	$ 16,400,000	$ 5,100,000	$ 8,600,000		$ 45,068,000	$ 18,606,000	$ 33,897,000
Price per share on NYSE mkt | $ / shares		$ 3.09	$ 3.09
Stock price per share | $ / shares	$ 2.60			$ 2.70		$ 2.39	$ 3.19	$ 3.29
Hadasit Bio-Holdings, Ltd [Member]
Ownership percentage, noncontrolling owners		21.20%	21.20%
OncoCyte Corporation [Member]
Price per share on NYSE mkt | $ / shares									$ 4.65	$ 4.65			$ 4.85
Repayments of related party debt									$ 1,600,000
Ascendance Biotechnology, Inc [Member]
Receivables from related party									$ 200,000	$ 200,000
Asterias Biotherapeutics [Member]
Price per share on NYSE mkt | $ / shares									$ 2.25	$ 2.25	$ 4.60			$ 3.02
Receivables from related party											$ 300,000
Net payables to related party									$ 33,000	$ 33,000
AgeX Therapeutics, Inc [Member]
Additional common shares purchased | shares										421,500
Additional common stock shares purchased price per share | $ / shares									$ 2	$ 2
Common stock issued to unaffiliated and existing investors | shares										300,000
Common stock price per share issued to unaffiliated and existing investors | $ / shares									$ 2.81	$ 2.81
Maximum [Member] | OncoCyte Corporation [Member]
Term of payment										30 days
Cell Cure Neurosciences, Ltd. [Member]
Carrying value of convertible notes									$ 1,865,000	$ 1,865,000
Amount of accrued interest									2,544,000	2,544,000
Unamortized debt discount									$ 679,000	$ 679,000
Cell Cure Neurosciences, Ltd. [Member] | Hadasit Bio-Holdings, Ltd [Member] | Common Stock [Member]
Common shares issued | shares		1,220,207
Common shares issued value		$ 3,800,000
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member]
Convertible notes bear a stated interest rate									3.00%	3.00%
Conversion price | $ / shares									$ 20	$ 20
Accrued interest, payable period										3 years
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member] | Hadasit Bio-Holdings, Ltd [Member] | Common Stock [Member]
Common shares issued | shares		2,776,662
Common shares issued value		$ 8,600,000
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member] | Minimum [Member]
Estimated fair market value per share | $ / shares										$ 28
Intrinsic value per share | $ / shares										$ 8
Effective annual interest rate									11.00%	11.00%
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes [Member] | Maximum [Member]
Estimated fair market value per share | $ / shares										$ 40
Intrinsic value per share | $ / shares										$ 20
Effective annual interest rate									23.00%	23.00%

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative)	Oct. 17, 2017USD ($)$ / sharesshares	Oct. 04, 2017shares	Aug. 17, 2017USD ($)$ / sharesshares	Jul. 10, 2017USD ($)$ / sharesshares	Jul. 10, 2017USD ($)$ / sharesshares	Feb. 15, 2017USD ($)$ / sharesshares	Jul. 05, 2016USD ($)shares	Jun. 16, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Oct. 31, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Jun. 06, 2017	Apr. 06, 2017USD ($)$ / shares	Feb. 17, 2017	May 13, 2016shares
Preferred shares, shares authorized												2,000,000	2,000,000
Preferred shares, shares issued
Preferred shares, shares outstanding
Common stock, shares authorized												150,000,000	150,000,000
Common stock, no par value | $ / shares
Common stock, issued												126,866,000	103,396,000
Common stock, outstanding												126,866,000	102,776,000
Treasury stock, shares													620,000
Number of common stock issued value | $												$ 45,068,000	$ 18,606,000	$ 33,897,000
Noncontrolling interest | $												$ 1,622,000	12,580,000
Ownership percentage				99.80%	99.80%							20.00%
Noncash expense | $												$ 3,932,000	7,951,000	11,050,000
Contribution Agreement [Member]
Ownership percentage			85.40%
Proportional transfer of carrying value | $			$ 5,500,000
General and Administrative Expense [Member]
Noncash expense | $												$ 3,000,000	5,343,000	$ 7,783,000
Maximum [Member]
Ownership percentage																	50.00%
Cantor Fitzgerald & Co [Member]
Common stock, no par value | $ / shares
Aggregate offering price | $																$ 25,000,000
Percentage of commission payable												3.00%
Alfred D. Kingsley [Member]
Number of common stock shares sold			300,000
Purchase price, per share | $ / shares			$ 2.81
Acquisition of common shares			300,000
Number of shares acquired from subsidiary in terms of exchange			421,500
OncoCyte [Member]
Noncontrolling interest | $													4,000,000
Asterias Biotherapeutics [Member]
Noncontrolling interest | $													$ 18,300,000
Warrants issued to purchase ordinary shares																		2,959,559
Asterias Biotherapeutics [Member] | Maximum [Member]
Ownership percentage													50.00%
Cell Cure Neurosciences, Ltd. [Member]
Charge to equity, value | $												$ 10,100,000
Proportional transfer of carrying value | $												$ 3,500,000
Number of stock options exercised to purchase ordinary shares		4,400
Cell Cure Neurosciences, Ltd. [Member] | Maximum [Member]
Ownership percentage		99.80%
Cell Cure Neurosciences, Ltd. [Member] | Minimum [Member]
Ownership percentage		98.80%
OrthoCyte Corporation [Member]
Number of stock options exercised to purchase ordinary shares												51,000
OrthoCyte Corporation [Member] | Maximum [Member]
Ownership percentage												100.00%
OrthoCyte Corporation [Member] | Minimum [Member]
Ownership percentage												99.80%
Common Stock [Member]
Number of common stock shares sold	11,057,693				4,924,542	7,453,704	1,098,326	7,322,176		1,600,000	2,607,401	18,511,000	8,420,000	10,738,000
Purchase price, per share | $ / shares	$ 2.60					$ 2.70		$ 2.39		$ 3.19	$ 3.29
Number of common stock issued value | $	$ 26,700,000				$ 15,200,000	$ 18,500,000	$ 2,200,000	$ 16,400,000		$ 5,100,000	$ 8,600,000	$ 45,068,000	$ 18,606,000	$ 33,897,000
Number of stock options exercised to purchase ordinary shares												9,000		155,000
Common Stock [Member] | Certain Investment [Member]
Number of common stock shares sold										6,530,612
Purchase price, per share | $ / shares										$ 3.13
Number of common stock issued value | $										$ 20,400,000
Common Stock [Member] | OncoCyte [Member]
Number of common stock shares sold									4,700,000	246,356
Shares conversion ratio									20
Equity method investment description									As a result of this distribution, BioTime recorded a reduction in the carrying value of its investment in OncoCyte with a corresponding increase to noncontrolling interests in OncoCyte in the amount of $712,000, representing the reduction in BioTime’s ownership in OncoCyte by 18.7% from 76.5% to 57.8%.
Reduction in equity method investment | $									$ 712,000
Taxable gain | $									$ 7,400,000
OncoCyte [Member]
Treasury stock, shares													619,706
Hadasit Bio-Holdings, Ltd [Member]
Ownership percentage, noncontrolling owners				21.20%	21.20%
Warrants issued to purchase ordinary shares				24,566	24,566
Warrants exercise price per share | $ / shares				$ 40.5359	$ 40.5359
Warrants exercisable term					5 years
Hadasit Bio-Holdings, Ltd [Member] | Other Long-term Liabilities [Member]
Noncash expense | $												$ 535,000
Hadasit Bio-Holdings, Ltd [Member] | Common Stock [Member] | Cell Cure Neurosciences, Ltd. [Member]
Number of common stock shares sold				1,220,207
Number of common stock issued value | $				$ 3,800,000
Teva Pharmaceutical Industries, Ltd [Member]
Ownership percentage, noncontrolling owners				16.10%	16.10%
HBL And Teva [Member]
Number of common stock shares sold					2,147,880
Number of common stock issued value | $					$ 6,600,000
Cell Cure Neurosciences, Ltd. [Member]
Ownership percentage				62.50%	62.50%
Cell Cure Neurosciences, Ltd. [Member] | General and Administrative Expense [Member]
Noncash expense | $												555,000
AgeX [Member]
Number of common stock shares sold			4,950,000
Number of common stock issued value | $			$ 10,000,000
Number of shares acquired from subsidiary in terms of exchange			28,800,000
Ownership percentage			85.40%
Cash contributed to acquire subsidiary | $												100,000
AgeX [Member] | License Agreement [Member]
Proportional transfer of carrying value | $												$ 8,200,000
ReCyte Therapeutics, Inc. [Member]
Ownership percentage												95.00%
LifeMap Sciences, Inc. [Member]
Ownership percentage												82.00%			100.00%
LifeMap Sciences, Inc. [Member] | Maximum [Member]
Ownership percentage															82.00%
LifeMap Sciences, Inc. [Member] | Minimum [Member]
Ownership percentage															78.00%
Ascendance Biotechnology, Inc [Member]
Ownership percentage												44.00%

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Activity Related to Warrants (Details) - Warrant [Member] - $ / shares		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016	Dec. 31, 2015
Numbers of Warrant Shares Outstanding Beginning Balance		9,395		10,110	9,195
Numbers of Warrant Shares Exercised					(4)
Numbers of Warrant Shares Warrant adjustment	[1]				919
Numbers of Warrant Shares Expired				(715)
Numbers of Warrant Shares Outstanding Ending Balance		9,365	[2]	9,395	10,110
Per share exercise price Outstanding Beginning Balance		$ 4.55		$ 4.55	$ 5
Per share exercise price Exercised					5
Per share exercise price Expired				4.55
Per share exercise price Outstanding Ending Balance		4.55	[2]	4.55	4.55
Weighted Average Exercise Price Outstanding Beginning Balance		4.55		4.55	5
Weighted Average Exercise Price Exercised					5
Weighted Average Exercise Price Expired				4.55
Weighted Average Exercise Price Outstanding Ending Balance		$ 4.55	[2]	$ 4.55	$ 4.55
[1]	The number of shares issuable upon the exercise of the warrants was adjusted as a result of the distribution of OncoCyte common stock to BioTime shareholders during December 2015.
[2]	The 9,394,862 outstanding warrants will expire, if unexercised, beginning June 5, 2018 through September 30, 2018.

Shareholders' Equity - Schedu57

Shareholders' Equity - Schedule of Activity Related to Warrants (Details) (Parenthetical) - Warrants [Member]	12 Months Ended
	Dec. 31, 2017shares
Number of outstanding warrants	9,394,862
Warrant expiration	beginning June 5, 2018 through September 30, 2018

Stock Option Plans (Details Nar

Stock Option Plans (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
2012 Equity Incentive Plan [Member]
Common shares reserved for future issuance	16,000,000
Unrecognized compensation costs related to unvested stock options	$ 3,700
Expense recognized, weighted average period	2 years 5 months 9 days
2002 Plan and 2012 Plan [Member]
Weighted-average estimated fair value of stock options granted	$ 1.65	$ 1.69	$ 2.13
2012 Plan [Member]
Common shares vested issued in lieu of cash		81,603
Number of shares available for grant		163,000

Stock Option Plans - Schedule o

Stock Option Plans - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 3,932	$ 7,951	$ 11,050
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	932	2,608	3,267
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 3,000	$ 5,343	$ 7,783

Stock Option Plans - Schedule60

Stock Option Plans - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) - 2002 Plan and 2012 Plan [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years 6 months 18 days	5 years 9 months 29 days	5 years 7 months 13 days
Risk-free interest rates	1.83%	1.45%	1.70%
Volatility	58.76%	61.24%	65.82%
Dividend yield	0.00%	0.00%	0.00%

Stock Option Plans - Schedule61

Stock Option Plans - Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity (Details) - $ / shares		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock Option 2002 Plan and 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance		2,894,000	5,257,000	668,000
Shares Available for Grant, Increase to option pool		6,000,000		6,000,000
Shares Available for Grant, RSUs			(200,000)
Common stock issued to consultant in lieu of cash			(28,000)
Common stock issued to employee for bonuses in lieu of cash			(135,000)
Shares Available for Grant, Exercised
Shares Available for Grant, Temporary restriction by Board on available pool	[1]	(5,000,000)
Shares Available for Grant Restricted stock units vested
Shares Available for Grant End of the period		2,485,000	2,894,000	5,257,000
Number of Options Outstanding, Beginning balance		6,958,000	5,194,000	3,974,000
Number of Options Outstanding, Increase in option pool
Number of Options Outstanding, Temporary restriction by Board on available pool	[1]
Number of Options Outstanding, Options exercised		(9,000)		(156,000)
Number of Options Outstanding, Common stock issued to consultant in lieu of cash
Number of Options Outstanding, Common stock issued to employee for bonuses in lieu of cash
Number of Options Outstanding, RSUs
Number of Options Outstanding, End balance		8,043,000	6,958,000	5,194,000
Number of RSUs Outstanding, Beginning balance		100,000
Number of RSUs Outstanding, Restricted stock units vested		(38,000)	100,000
Number of RSUs Outstanding, End balance		62,000	100,000
Weighted Average Exercise Price of Options Outstanding, beginning balance		$ 3.60	$ 3.93	$ 4.04
Weighted Average Exercise Price of Options, Increase in option pool
Weighted Average Exercise Price of Options, RSUs
Weighted Average Exercise Price of Options, Common stock issued to consultant in lieu of cash
Weighted Average Exercise Price of Options, Common stock issued to employee for bonuses in lieu of cash
Weighted Average Exercise Price of Options, Options exercised		2.66		4
Weighted Average Exercise Price of Options, Outstanding end balance		$ 3.38	$ 3.60	$ 3.93
Stock Option Plan Of 2002 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant Options Forfeited/cancelled/expired
Number of Options Outstanding, Options forfeited/cancelled/expired			(236,000)	(35,000)
Weighted Average Exercise Price of Options, Options forfeited/cancelled			$ 5.17	$ 6.72
Stock Option Plan Of 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Options Granted		(1,954,000)	(2,315,000)	(1,650,000)
Shares Available for Grant Options Forfeited/cancelled/expired		545,000	315,000	239,000
Number of Options Outstanding, Increase in option pool			2,315,000
Number of Options Outstanding, Options granted		1,954,000		1,650,000
Number of Options Outstanding, Options forfeited/cancelled/expired		(860,000)	(315,000)	(239,000)
Weighted Average Exercise Price of Options, Options granted		$ 3.04	$ 3.03	$ 3.72
Weighted Average Exercise Price of Options, Options forfeited/cancelled		$ 4.43	$ 3.77	$ 3.82
[1]	On October 13, 2017, BioTime's Board of Directors determined to temporarily set a limit on shares available for grants of share-based awards pursuant to the 2012 Plan. While that limit remains in place, BioTime will not grant share-based awards for more than a total of approximately 2.5 million of the common shares remaining available for awards under the 2012 Plan.

Stock Option Plans - Schedule62

Stock Option Plans - Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity (Details) (Parenthetical)	Oct. 13, 2017shares
Stock Option Plan Of 2012 [Member]
Number of common shares remaining available for awards	2,500,000

Stock Option Plans - Schedule63

Stock Option Plans - Schedule of Options Outstanding and Exercisable Range of Exercise Prices (Details) - 2002 Plan and 2012 Plan [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Range of Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 2.52
Range of Exercise Prices, Upper Range Limit	$ 3.96
Number Outstanding | shares	6,883
Options Outstanding, Weighted Avgerage Contractual Life (years)	7 years 2 months 23 days
Options Outstanding, Weighted Average Exercise Price	$ 3.24
Number Exercisable | shares	3,190
Options Exercisable, Weighted Average Exercise Price	$ 3.35
Range of Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Range Limit	4.02
Range of Exercise Prices, Upper Range Limit	$ 4.95
Number Outstanding | shares	1,150
Options Outstanding, Weighted Avgerage Contractual Life (years)	3 years 2 months 1 day
Options Outstanding, Weighted Average Exercise Price	$ 4.22
Number Exercisable | shares	1,048
Options Exercisable, Weighted Average Exercise Price	$ 4.22
Range of Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Range Limit	5.02
Range of Exercise Prices, Upper Range Limit	$ 8.58
Number Outstanding | shares	10
Options Outstanding, Weighted Avgerage Contractual Life (years)	2 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 32.62
Number Exercisable | shares	10
Options Exercisable, Weighted Average Exercise Price	$ 7.47
Range of Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Range Limit	2.52
Range of Exercise Prices, Upper Range Limit	$ 8.58
Number Outstanding | shares	8,043
Options Outstanding, Weighted Avgerage Contractual Life (years)	6 years 7 months 21 days
Options Outstanding, Weighted Average Exercise Price	$ 3.38
Number Exercisable | shares	4,248
Options Exercisable, Weighted Average Exercise Price	$ 3.57

Commitments and Contingencies64

Commitments and Contingencies (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)ft²m²Integer	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2017ILS (₪)ft²m²	Dec. 10, 2015USD ($)ft²
Operating Leased Assets [Line Items]
Security deposit	$ 847,000
Rent expense	1,100	$ 1,500	$ 2,100
Maximum [Member]
Operating Leased Assets [Line Items]
Tenant improvement allowance	$ 1,400,000
NIS [Member]
Operating Leased Assets [Line Items]
Base rent | ₪				₪ 63,402
Cell Cure Neurosciences, Ltd. [Member] | Minimum [Member]
Operating Leased Assets [Line Items]
Royalty revenue percentage		15.00%
Cell Cure Neurosciences, Ltd. [Member] | Maximum [Member]
Operating Leased Assets [Line Items]
Royalty revenue percentage	25.00%
Milestone payments	$ 3,500,000
New Alameda Lease [Member]
Operating Leased Assets [Line Items]
Leased area | ft²					30,795
Number of buildings for lease | Integer	2
Lease term	7 years
Number of years lease can be extended	5 years
Lease commencement date	Feb. 1, 2016
Tenant improvement allowance					$ 1,400
Amount due to landlord	$ 1,200
Base rent					$ 64,670
Base rent increase rate					3.00%
Security deposit					$ 847,000
Security deposit reduction in value after first twenty four months of lease term					423,000
Additional reduction in value after first thirty six months of lease term					$ 346,000
Reporting Entities [Member] | Office Space in New York City [Member]
Operating Leased Assets [Line Items]
Base rent	5,050
Office and Laboratory Space, Jerusalem, Israel [Member]
Operating Leased Assets [Line Items]
Base rent	$ 18,247
Office and Laboratory Space, Jerusalem, Israel [Member] | Cell Cure [Member]
Operating Leased Assets [Line Items]
Leased area | m²	1,128			1,128
Number of years lease can be extended	5 years
Area of land | ft²	12,142			12,142
Lease expiration	a lease that expires between May 30, 2019 and December 31, 2020
License fees and related expenses	$ 221,000	$ 180,000	$ 282,000
Office and Laboratory Space, Jerusalem, Israel [Member] | Cell Cure [Member] | Minimum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees	135,000
Office and Laboratory Space, Jerusalem, Israel [Member] | Cell Cure [Member] | Maximum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees	$ 150,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Operating and Capital Lease Payments (Details) $ in Thousands	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 1,266
2,019	1,100
2,020	1,030
2,021	918
2,022	946
Thereafter	86
Total	5,346
2,018	31
2,019	37
2,020	37
2,021	37
2,022	37
Thereafter	16
Total	195
Less amounts representing interest	(44)
Present value of net minimum lease payments	$ 151

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	Dec. 22, 2017	Feb. 17, 2017	May 13, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 06, 2017
Repatriation tax foreign earnings in federal income	$ 227
Net deferred tax assets				$ 8,900
Federal income tax rate				34.00%	34.00%	34.00%
Net operating loss carryforwards for federal tax purposes				$ 162,600
Foreign net operating loss carryforwards				65,200
Net operating loss carryforwards for state tax purposes				95,000
Deferred income tax benefit						$ (4,516)
Deferred income tax expense (benefit), federal						4,800
Deferred income tax expense (benefit), state taxes						$ 290
Net operating loss carryforwards change in ownership control				50.00%
Federal and State [Member]
Net operating losses expiration date				between 2018 and 2036
Federal [Member]
Net operating losses expiration date				between 2018 and 2036
Tax credit carryforwards				$ 3,300
State Tax [Member]
Tax credit carryforwards				3,300
LifeMap Sciences, Ltd. [Member]
Net operating loss carryforwards for federal tax purposes				17,600
OncoCyte Deconsolidation [Member]
Gain on deconsolidation of asterias		$ 71,700		2,900
Asterias Deconsolidation [Member]
Gain on deconsolidation of asterias			$ 49,000	51,100	$ 34,300
LifeMap Solutions, Inc [Member]
Taxable gain on asset transfer				3,700
Federal alternative minimum tax payable				$ 22,000
LifeMap Solutions, Inc [Member] | Debt Conversion Agreement [Member]
Iintercompany indebtedness							$ 8,700
Net operating loss carryforwards							$ 3,300
Maximum [Member]
Deferred tax assets and liabilities re-rated percentage				34.00%
Minimum [Member]
Deferred tax assets and liabilities re-rated percentage				21.00%

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 55,608	$ 78,116
Research and development and other credits	6,548	7,645
Patents and licenses	910	(67)
Equity method investments at fair value	(23,946)	(40,258)
Stock options	713	1,529
Other, net	812	2,248
Total	40,645	49,213
Valuation allowance	(40,645)	(49,213)
Net deferred tax assets

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Rate Reconciliation (Details)	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Computed tax benefit at federal statutory rate		34.00%	34.00%	34.00%
Research and development and other credits		2.00%	(3.00%)	2.00%
Re-rate of federal net deferred tax assets		(38.00%)	0.00%	0.00%
Permanent differences		(8.00%)	2.00%	(4.00%)
Change in valuation allowance		(32.00%)	(63.00%)	(34.00%)
Establish deferred tax liability for OncoCyte shares at deconsolidation		17.00%	0.00%	0.00%
State tax benefit, net of effect on federal income taxes	21.00%	27.00%	24.00%	10.00%
Foreign rate differential		(2.00%)	6.00%	(1.00%)
Total		0.00%	0.00%	7.00%

Segment Information (Details Na

Segment Information (Details Narrative)	12 Months Ended
	Dec. 31, 2017Segment
Segment Reporting [Abstract]
Number of operating segments	1

Enterprise-Wide Disclosures (De

Enterprise-Wide Disclosures (Details Narrative) - Life Map Sciences [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Payment received from research project	$ 1,400	$ 972
Advertising revenue	1,200	668
Revenues of royalty and commission fees	$ 168	$ 304

Enterprise-Wide Disclosures - S

Enterprise-Wide Disclosures - Schedule of Geographic Area Information (Details) - USD ($) $ in Thousands		3 Months Ended										12 Months Ended
		Dec. 31, 2017		Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Total revenues		$ 945		$ 1,636	$ 376	$ 333	$ 1,103		$ 1,441	$ 1,171	$ 1,848	$ 3,458		$ 5,923		$ 7,036
Long-lived assets		5,533	[1]				5,529	[2]				5,533	[1]	5,529	[2]
United States [Member]
Total revenues												1,651		4,497		5,976
Foreign [Member]
Total revenues	[3]											1,807		1,426		$ 1,060
Long-lived assets		2,787	[1]				2,111	[2]				2,787	[1]	2,111	[2]
Domestic [Member]
Long-lived assets		$ 2,746	[1]				$ 3,418	[2]				$ 2,746	[1]	$ 3,418	[2]
[1]	Reflects the effect of the OncoCyte Deconsolidation.
[2]	Reflects the effect of the Asterias Deconsolidation.
[3]	Foreign revenues are primarily earned in Israel.

Enterprise-Wide Disclosures -72

Enterprise-Wide Disclosures - Schedule of Sources of Revenues (Details)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
CIRM Grant Income [Member]
Percentage of total revenues	[1]	0.00%	38.00%	42.70%
NIH Grant Income [Member]
Percentage of total revenues	[2]	5.00%	0.00%	6.50%
IIA (formerly OCS) Grant Income (Cell Cure, Israel) [Member]
Percentage of total revenues		43.20%	24.00%	14.40%
Subscriptions, Advertising and Other (various customers) [Member]
Percentage of total revenues	[3]	49.40%	35.00%	29.40%
Other [Member]
Percentage of total revenues		2.40%	3.00%	7.00%
[1]	Reflects income from grants to Asterias from the California Institute for Regenerative Medicine (CIRM) prior to the Asterias Deconsolidation.
[2]	For 2017, reflects income from grants to BioTime from the National Institutes of Health (NIH). For 2015, reflects income from grants to ReCyte from the NIH.
[3]	For each of 2017 and 2016, one individual customer represents greater than 5% of total revenues. For 2015, no individual customer greater than 5% of total revenues.

Enterprise-Wide Disclosures -73

Enterprise-Wide Disclosures - Schedule of Sources of Revenues (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Sales Revenue, Net [Member] | Customer [Member]
Concentration risk percentage	5.00%	5.00%	5.00%

Selected Quarterly Financial 74

Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Revenues, net	$ 945	$ 1,636	$ 376	$ 333	$ 1,103	$ 1,441	$ 1,171	$ 1,848	$ 3,458	$ 5,923	$ 7,036
Operating expenses	10,508	11,149	10,694	11,595	12,356	10,996	15,574	25,606	43,946	64,532	71,738
Loss from operations	(9,563)	(9,513)	(8,564)	(11,262)	(11,253)	(9,555)	(14,403)	(23,758)	(38,902)	(58,967)	(65,809)
Net income (loss) attributable to BioTime	$ (71,934)	$ 14,321	$ (11,651)	$ 49,288	$ (4,945)	$ 31,199	$ 24,549	$ (17,112)	$ (19,976)	$ 33,572	$ (46,991)
Basic net income (loss) per share	$ (0.58)	$ 0.12	$ (0.11)	$ 0.46	$ (0.05)	$ 0.30	$ 0.26	$ (0.19)	$ (0.17)	$ 0.35	$ (0.59)

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Lease Agreement [Member] - Subsequent Event [Member]	Feb. 28, 2018USD ($)Integer$ / sharesshares	Jan. 28, 2018USD ($)ft²m²	Jan. 28, 2018ILS (₪)ft²m²
Additional area of land | m²		934	934
Area of land | ft²		10,054	10,054
Lease expiration date		Dec. 31, 2025	Dec. 31, 2025
Extended lease term		5 years	5 years
Lease expenses | $		$ 27,000
AgeX [Member]
Warrant to purchase common stock | shares	1,473,600
Warrant exercise price | $ / shares	$ 0.50
Proceeds from warrants | $	$ 736,800
Warrant exercisable price | $ / shares	$ 2.50
AgeX [Member] | January 31, 2019 [Member]
Common stock exercise price | $ / shares	$ 3.75
Number of trading days | Integer	20
NIS [Member]
Lease expenses | ₪			₪ 93,470
Maximum [Member]
Leasehold improvement construction allowance | $		$ 1,200,000
Maximum [Member] | NIS [Member]
Leasehold improvement construction allowance | ₪			₪ 4,000,000